US Pre-Market SEC Filings Roundup — March 04, 2026

03-03-2026

This DEF 14A proxy statement solicits shareholder votes for the election of board members at the virtual annual meeting on April 16, 2026, for Nuveen Preferred & Income Opportunities Fund (JPC) and 15 other Nuveen closed-end funds. For JPC, holders of Common and Preferred Shares voting together will elect four Class II Board Members, while Preferred Share holders voting separately will elect two Board Members. No financial performance data or period-over-period comparisons are provided; the filing focuses solely on governance and meeting logistics.

• ·Record date: February 9, 2026
• ·Proxy materials mailed on or about March 6, 2026
• ·Virtual meeting access: meetnow.global/M6VY4FD at 2:00 p.m. Central time
• ·Intermediary registration deadline: 5:00 p.m. ET, 3 business days prior to meeting
• ·Quorum: majority of shares for most votes; 33 1/3% of Preferred Shares for their separate election
• ·Former names include Nuveen Preferred Income Opportunities Fund (changed 2012)

03-03-2026

TrueBlue, Inc. issued a press release responding to misleading statements from activist investor EHS Investments amid an ongoing proxy contest for the 2026 Annual Meeting of Shareholders, highlighting its second consecutive quarter of organic revenue growth on February 18, 2026, and plans for improving profitability and margins. The company detailed active engagement with EHS, including a recent settlement proposal and attempted counterproposal meeting, alongside board refreshment appointing William Greenblatt and William Seward—endorsed by its largest shareholder—while two existing directors will step down. TrueBlue affirmed openness to constructive dialogue, with Barclays as financial advisor and Sidley Austin LLP as legal counsel.

• ·TrueBlue's proxy statement with background on EHS engagement to be filed in coming weeks.
• ·Recent director Forms 3/4 filed February 2024-2026 for Colleen B. Brown, William C. Goings, Garrett R. Ferencz, Kim Harris Jones, R. Chris Kreidler, Sonita Lontoh, Taryn R. Owen, Paul G. Reitz, Jeffrey B. Sakaguchi, Kristi A. Savacool, Carl R. Schweihs.
• ·2026 Annual Meeting of Shareholders upcoming; BLUE proxy card to be distributed.

03-03-2026

This DEF 14A proxy statement solicits votes for the virtual annual shareholder meeting of Nuveen NASDAQ 100 Dynamic Overwrite Fund (QQQX) and multiple other Nuveen funds on April 16, 2026, at 2:00 p.m. Central time. For QQQX, shareholders will vote to elect four Class II Board Members by holders of Common Shares. The record date for voting eligibility is February 9, 2026, with no financial performance data or period comparisons disclosed.

• ·Annual Meeting held virtually via live webcast at meetnow.global/M6VY4FD
• ·Registration for intermediary-held shares required by 5:00 p.m. ET, three business days prior
• ·Proxy mailed on or about March 6, 2026
• ·Quorum: Majority of shares for most votes; 33 1/3% of Preferred Shares for certain elections

03-03-2026

This DEF 14A joint proxy statement solicits shareholder votes for the virtual annual meetings of 16 Nuveen closed-end funds, including Nuveen Municipal Credit Opportunities Fund (NMCO), on April 16, 2026, primarily to elect Board Members (Trustees). For NMCO and similar funds, shareholders will vote on four Class II Board Members (common and preferred shares together) and two Board Members (preferred shares only); other funds have varying election structures for Class I, II, or III members. No financial results, performance metrics, or changes are disclosed.

• ·Record date: February 9, 2026
• ·Annual Meeting: April 16, 2026 at 2:00 p.m. Central time, virtual via meetnow.global/M6VY4FD
• ·Proxy mailed on or about March 6, 2026
• ·Quorum: Majority of shares for most votes; 33 1/3% of Preferred Shares for certain elections
• ·Registration for virtual attendance required 3 business days prior for intermediary-held shares

03-03-2026

Nuveen Multi-Market Income Fund (JMM) and 15 other Nuveen funds have issued a joint proxy statement for their annual shareholder meetings on April 16, 2026, to elect board members. For JMM specifically, shareholders will vote to elect four Class I Board Members, four Class II Board Members, and four Class III Board Members. The record date for voting eligibility is February 9, 2026, with the virtual meeting accessible via meetnow.global/M6VY4FD.

• ·Shareholder record date: February 9, 2026
• ·Annual Meeting date and time: April 16, 2026 at 2:00 p.m. Central time (virtual only)
• ·Proxy materials mailed on or about March 6, 2026
• ·Quorum requirement: Majority of shares entitled to vote; 33 1/3% for Preferred Shares elections in certain funds
• ·Registration for virtual attendance required 3 business days prior for shares held through intermediaries

03-03-2026

This joint DEF 14A proxy statement solicits votes from shareholders of Nuveen Multi-Asset Income Fund (NMAI) and 15 other Nuveen funds for annual meetings on April 16, 2026, to elect board members, including four Class II Board Members for NMAI. The meetings are virtual only, with record date February 9, 2026; no financial results or performance metrics are disclosed. Voting applies to common and preferred shares as specified, with quorums at majority or 33 1/3% levels.

• ·Record date: February 9, 2026
• ·Proxy materials mailed on or about March 6, 2026
• ·Virtual meeting link: meetnow.global/M6VY4FD
• ·Registration for intermediary-held shares due 3 business days prior by 5:00 p.m. ET
• ·For Multi-Market Income: elect 4 Class I, 4 Class II, 4 Class III Board Members

03-03-2026

abrdn Gold ETF Trust reported net assets of $7.33B as of Dec 31, 2025, up from $3.76B in 2024, driven by a $2.66B total gain on gold investments and $2.65B change in net assets from operations, reflecting a 64.77% total return and NAV per share rising to $41.06 from $24.92. However, sponsor's fees increased 65% YoY to $9.3M amid higher AUM, while the expense ratio remained flat at 0.17%. Weighted average shares outstanding grew 15% to 165M.

• ·Cost of investment in gold: $3.56B at Dec 31, 2025 vs $2.48B at Dec 31, 2024.
• ·Realized gain on gold distributed for redemptions: $162M in 2025 vs $53M in 2024 (+203%).
• ·Change in unrealized gain on gold: $2.50B in 2025 vs $661M in 2024 (+278%).
• ·Fees payable to Sponsor: $1.1M at Dec 31, 2025 vs $0.5M at Dec 31, 2024.

03-03-2026

Nuveen Mortgage & Income Fund (JLS) has filed a DEF 14A proxy statement soliciting shareholder votes to elect four Class II Board Members at the virtual annual meeting on April 16, 2026, with a record date of February 9, 2026. This is a joint proxy for multiple Nuveen funds with similar governance matters. No financial results, performance metrics, or material changes are disclosed.

• ·Filing date: March 3, 2026; proxy materials mailed on or about March 6, 2026
• ·Virtual meeting access: meetnow.global/M6VY4FD; registration required for intermediary-held shares 3 business days prior
• ·Quorum: Majority of shares entitled to vote; 33 1/3% for Preferred Shares elections in certain funds

03-03-2026

Pono Capital Four, Inc., a Cayman Islands blank check company (SPAC), filed Amendment No. 1 to its S-1 registration statement on March 3, 2026, for an IPO of 15,000,000 units at $10.00 each to raise $150M, with underwriters' 45-day over-allotment option for 2,250,000 additional units. Sponsor Mehana Ventures LLC and investors committed to $2.5M in private placement units closing simultaneously, while sponsor holds 7,392,857 Class B founder shares (purchased for $25,000) for ~30% post-IPO ownership on as-converted basis; however, this structure causes immediate substantial dilution to public shareholders and potential further dilution from anti-dilution rights.

• ·Underwriters have full discretion on allocations; non-managing sponsor investors capped at 9.9% of IPO units if participating.
• ·No specific business combination target selected; pursuits open to any industry/geography.
• ·Registrant qualifies as non-accelerated filer, smaller reporting company, and emerging growth company.

03-03-2026

CPS Technologies Corp reported strong revenue growth of 54% YoY to $32.6M in FY2025 from $21.1M in FY2024, swinging gross margin to a profit of $5.3M from a $0.1M loss and achieving net income of $0.4M versus a $3.1M loss, bolstered by $9.4M in common stock issuance that expanded total assets to $29.5M from $18.9M. However, SG&A expenses rose 14% to $4.8M, limiting operating income to a slim $0.4M (1.4% margin), while operating cash flow was modest at $0.2M after a $1.3M inventory increase and heavy $9.0M investment in marketable securities. Total stockholders' equity grew to $24.6M, driven by the equity raise.

• ·Inventory reserve for obsolescence increased to $0.7M from $0.5M.
• ·Deferred taxes decreased to $2.3M from $2.5M.
• ·Weighted average basic shares outstanding increased 5% to 15.3M.

03-03-2026

Nuveen Minnesota Quality Municipal Income Fund (NMS) and 15 other Nuveen closed-end funds have issued a joint proxy statement for their Annual Meetings of Shareholders on April 16, 2026, at 2:00 p.m. Central time, to elect Board Members. For NMS, the vote includes electing four Class II Board Members by holders of Common Shares and Preferred Shares voting together as a single class, and two Board Members by Preferred Shares voting separately. The meetings will be held virtually via live webcast with no physical location.

• ·Record date for shareholders entitled to vote: February 9, 2026
• ·Proxy statement mailing date: on or about March 6, 2026
• ·Virtual meeting access: meetnow.global/M6VY4FD (requires control number or advance registration for intermediary-held shares)
• ·Quorum requirement: majority of shares entitled to vote (33 1/3% for Preferred Shares elections)

03-03-2026

The abrdn Silver ETF Trust reported shares at redeemable value surging 282% YoY to $5.43B as of December 31, 2025 from $1.42B in 2024, with outstanding shares up 54% to 79.25M, driven by silver spot price rising 149% to $71.99/oz. However, global silver mine production grew only 1% YoY to 819.7M oz in 2024, total supply increased 2% to 1,015.1M oz while demand fell 3% to 1,164.1M oz, and segments like photography (-7% YoY), jewelry (-6% forecast for 2025), and silverware (-15% forecast) showed declines. This 10-K/A amendment, filed March 3, 2026, solely adds the omitted KPMG auditor's report and re-executed certifications to the original March 2, 2026 filing.

• ·Aggregate identifiable silver bullion inventories total 1,239.2M oz at year-end 2024, up 1% YoY, with London vaults down 3% to 827.5M oz but COMEX up 15% to 318.6M oz.
• ·Silver market deficit narrowed 26% YoY to -148.9M oz in 2024.
• ·As of Feb 26, 2026, outstanding shares at 76.55M, down from 79.25M at Dec 31, 2025.

03-03-2026

This joint definitive proxy statement for Nuveen Global High Income Fund (JGH) and 15 other Nuveen closed-end funds solicits shareholder votes for Board Member elections at virtual annual meetings on April 16, 2026, with varying numbers of Class I, II, or III trustees to be elected by Common Shares, Preferred Shares, or both depending on the fund. For JGH, four Class II Board Members are to be elected by Common Shares holders. No financial performance data or period comparisons are provided; the filing is purely procedural for governance matters.

• ·Record date: February 9, 2026
• ·Annual Meeting: April 16, 2026 at 2:00 p.m. Central Time (virtual via meetnow.global/M6VY4FD)
• ·Proxy materials mailed on or about March 6, 2026
• ·Intermediary registration deadline: 5:00 p.m. ET, 3 business days prior to meeting
• ·Quorum: majority of shares outstanding (33 1/3% for Preferred Shares elections in certain funds)
• ·Fiscal year end: December 31
• ·SEC file number: 811-22988

03-03-2026

The DEF 14A filing is a joint proxy statement for the annual shareholder meetings of multiple Nuveen funds, including Nuveen Floating Rate Income Fund (JFR), scheduled virtually on April 16, 2026, at 2:00 p.m. Central time. Shareholders are voting to elect Board Members: for JFR, six total (four Class II by Common and Preferred Shares together, two by Preferred Shares only). Record date is February 9, 2026; no financial performance data or changes reported.

• ·Record date: February 9, 2026
• ·Proxy materials mailed on or about March 6, 2026
• ·Virtual meeting access: meetnow.global/M6VY4FD
• ·Registration for intermediary-held shares required 3 business days prior by 5:00 p.m. ET
• ·Quorum: Majority of shares for most votes; 33 1/3% of Preferred Shares for certain elections

03-03-2026

B&G Foods completed several divestitures in 2025-2026, including Green Giant U.S. frozen to Seneca Foods in March 2026, Le Sueur U.S. to McCall Farms in August 2025, and Don Pepino to Violet Foods in May 2025, while agreeing to acquire College Inn and Kitchen Basics broth business (expected Q1 2026 close) and divest Green Giant Canada (expected Q2 2026). These moves aim to sharpen focus, improve margins, reduce costs and debt, but carry risks of failure to realize benefits. The company highlights substantial leverage risks, potential debt covenant breaches, tariff impacts, and future asset impairments amid operating challenges.

• ·Union contracts: Ankeny IA (Teamsters Local 238, Apr 2025-2031); Brooklyn NY (UFCW Local 342, Jan 2024-Dec 2027); Cincinnati OH (Employees Representation Assoc., May 2023-Apr 2027); Irapuato MX (CTM union, Apr 2023-open); Roseland NJ (Teamsters Local 863, Apr 2020-Mar 2026); Stoughton WI (Local 695, Mar 2021-Mar 2026); Terre Haute IN (Teamsters Local 135, Mar 2024-Mar 2027).
• ·Risks include inability to fund capex/dividends/acquisitions due to leverage, debt covenant compliance (leverage ratio, interest coverage), tariffs on China/Canada/Mexico, divestiture/acquisition integration failures, and goodwill/intangible impairments.

03-03-2026

Matthews International Funds d/b/a Matthews Asia Funds is seeking shareholder approval at special meetings on April 14, 2026, for the election of two trustees (Neal Andrews and Mark W. Headley) and new investment advisory/management agreements with Matthews International Capital Management, LLC, to replace current agreements that will terminate due to a pending change-of-control transaction at Matthews expected to close in Q2 2026. The transaction involves repurchasing ownership interests from RBC USA HoldCo Corporation, Mizuho Bank, Ltd., and Lovell Minnick Partners LLC affiliates, funded partly by increased stakes from G. Paul Matthews (to ~33%) and Mark W. Headley (to ~34%), with the Board unanimously recommending approval as there are no material changes to fees, management, or services. No performance disruptions or changes to portfolio management are anticipated.

• ·Board Meeting approving New Agreements: February 25-26, 2026
• ·First Special Meeting (Proposal 1: Trustee Election): 10:00 a.m. Pacific Time, April 14, 2026
• ·Second Special Meeting (Proposal 2: New Agreements): 10:30 a.m. Pacific Time, April 14, 2026
• ·New Agreements identical to Current Agreements except effective/termination dates
• ·Meetings held in person only, no virtual attendance

03-03-2026

Cortigent, Inc., a spin-off from Vivani Medical, Inc., has filed Amendment No. 16 to its S-1 registration statement for a firm commitment IPO of 1,500,000 shares of common stock at an anticipated $10.00 per share, targeting NYSE American listing under 'CRGT', with gross proceeds of $15M before expenses. The company develops investigational brain implant devices including the Orion Visual Prosthesis ($4B US TAM) and Stroke Recovery System ($6B annual US TAM), building on the discontinued Argus II system. Post-IPO, Vivani will own approximately 77% of voting power, making Cortigent a controlled company, amid very high investment risks and no guaranteed FDA approvals for commercial products.

• ·Completed 6-year Early Feasibility Study for Orion in March 2025 with promising results (5/6 subjects improved at 36 months)
• ·Orion received FDA Breakthrough Device designation
• ·Argus II was the only FDA-approved artificial vision device (under Humanitarian Device Exemption) but sales discontinued in 2019
• ·Devices are investigational and require FDA approval; no assurance of safety, efficacy, or commercialization
• ·Filing date: March 3, 2026; Registration No. 333-270700

03-03-2026

This DEF 14A proxy statement, filed March 3, 2026, solicits votes for the joint virtual annual meetings of Nuveen Credit Strategies Income Fund (JQC) and 15 other Nuveen funds on April 16, 2026, primarily to elect Board Members (Trustees). For JQC, shareholders will vote to elect six Board Members: four Class II by holders of Common and Preferred Shares voting together, and two by Preferred Shares holders only. The record date for shareholders entitled to vote is February 9, 2026.

• ·Annual Meeting at 2:00 p.m. Central Time, virtual only via meetnow.global/M6VY4FD
• ·Shareholders with intermediary-held shares must register 3 business days prior with legal proxy to attend virtually
• ·Quorum: majority of shares for most votes; 33 1/3% of Preferred Shares for their separate elections
• ·Proxy mailed on or about March 6, 2026

03-03-2026

Powell Max Ltd, a BVI-incorporated company with operations in Hong Kong, filed a Form F-3 registration statement on March 3, 2026, for the resale of 74,809,231 Class A Ordinary Shares by Selling Shareholders. The prospectus incorporates by reference the Annual Report on Form 20-F for the fiscal year ended December 31, 2024, and various Form 6-K reports, stating no reportable material changes have occurred since December 31, 2024. It highlights uncertainties in enforcing U.S. court judgments against the company and its officers due to its foreign incorporation and asset locations.

• ·Incorporated in British Virgin Islands (BVI); business address: 22/F., Euro Trade Centre, 13-14 Connaught Road Central, Central, Hong Kong.
• ·Appointed Cogency Global Inc. as agent for service of process in the United States.
• ·Incorporates Annual Report on Form 20-F for FY ended December 31, 2024 (filed April 28, 2025) and Form 6-K filings on May 2, 2025; May 23, 2025; August 14, 2025; September 5, 2025; September 23, 2025; September 25, 2025; December 2, 2025; December 16, 2025; December 31, 2025; January 9, 2026; February 10, 2026; February 11, 2026; February 13, 2026.
• ·Description of Class A Ordinary Shares in Form 8-A filed August 27, 2024.

03-03-2026

abrdn Palladium ETF Trust reported a strong turnaround for the year ended December 31, 2025, with change in net assets from operations of $321.9M, up from a $67.6M loss in 2024 and driven by $339.8M in unrealized gains on palladium investments, boosting net assets to $1.035B from $354M YoY (+192%). However, sponsor fees increased 84% YoY to $3.2M reflecting higher AUM, and realized losses on palladium distributions rose to $14.4M from $65.7M loss in 2024. Per share net asset increase was $65.50, compared to a $21.10 decline in 2024.

• ·Palladium receivable of $35.6M as of Dec 31, 2025.
• ·Fees payable to Sponsor: $0.5M (Dec 31, 2025) vs $0.2M (Dec 31, 2024).
• ·Autocatalysts accounted for 85% of net global palladium demand in 2022; European automotive demand declining.
• ·Major palladium supply from Russia and South Africa.
• ·Net investment loss per share YE 2025: $65.50 vs -$21.10 (2024) and -$56.28 (2023).

03-03-2026

This DEF 14A proxy statement solicits votes for the annual shareholder meeting of Nuveen Core Plus Impact Fund (NPCT) and 15 other Nuveen funds on April 16, 2026, held virtually, primarily to elect Board Members across various classes. For NPCT, shareholders will vote to elect four Class II Board Members (Common and Preferred shares voting together) and two Board Members (Preferred shares only). No financial performance data, metrics, or period-over-period comparisons are disclosed.

• ·Record date: February 9, 2026
• ·Meeting: Virtual only via meetnow.global/M6VY4FD at 2:00 p.m. Central time
• ·Proxy mailed on or about March 6, 2026
• ·Registration for intermediary-held shares required 3 business days prior

03-03-2026

This DEF 14A proxy statement solicits shareholder votes for the election of board members at the virtual annual meetings of Nuveen Core Equity Alpha Fund (JCE) and 15 other Nuveen closed-end funds on April 16, 2026, at 2:00 p.m. Central Time. For JCE, four Class II Board Members are to be elected by common shareholders. The record date for voting eligibility is February 9, 2026, with no financial performance metrics or period-over-period comparisons disclosed.

• ·Virtual meeting access: meetnow.global/M6VY4FD; registered shareholders use control number, intermediaries register 3 business days prior with legal proxy to shareholdermeetings@computershare.com
• ·Proxy mailing date: on or about March 6, 2026
• ·Quorum: majority of shares entitled to vote, except 33 1/3% for Preferred Shares elections in specified funds

03-03-2026

The abrdn Precious Metals Basket ETF Trust reported a massive increase in change in net assets from operations to $1.07B for the year ended December 31, 2025, up 526% YoY from $170.3M in 2024, driven by $1.076B total gain on bullion investments amid rising precious metals prices. Net assets grew to $2.58B from $1.04B YoY, with net increase per share surging to $99.74 from $17.48. However, sponsor's fees rose 57% YoY to $9.5M, reflecting higher AUM and weighted average shares up 10% to 10.7M.

• ·Net increase in net assets per share: $99.74 (2025) vs $17.48 (2024) vs $2.49 (2023)
• ·Q4 2025 change in net assets from operations: $504M, largest quarterly gain
• ·Gold cost basis Dec 31, 2025: $743M; market value $1.47B (98% unrealized gain implied)
• ·Silver cost basis Dec 31, 2025: $348M; market value $898M

03-03-2026

The abrdn Platinum ETF Trust's shares at redeemable value grew 181% YoY from $1.02B at December 31, 2024 to $2.86B at December 31, 2025, driven by a 121.8% surge in platinum spot price to $2,027 per ounce and an increase in outstanding shares from 12.2M to 15.55M. While the Trust showed strong growth, the platinum market experienced ongoing supply deficits with total demand exceeding supply in recent years, leading to negative movements in stocks (e.g., -774 thousand ounces in 2024). No declines were reported in Trust assets or shares outstanding.

• ·Platinum primary supply totaled 5,723 thousand ounces in 2024, down from 5,810 in 2023.
• ·World platinum demand was 7,869 thousand ounces in 2024 vs. supply of 7,095 thousand ounces.
• ·South Africa accounted for 72% of mine supply over 2015-2024.

03-03-2026

In FY2025 ended January 3, 2026, Eastern Co's gross margin declined to 22.9% from 24.7% in FY2024, and operating profit margin fell sharply to 4.3% from 7.4%, reflecting higher cost of products sold (77.1% vs. 75.3%) and selling/admin expenses (17.0% vs. 15.5%). However, liquidity strengthened with current ratio improving to 3.7 from 2.6 and total debt to equity dropping to 27% from 35%. Cash and equivalents decreased to $7.4M from $14.0M, while net cash from operations dropped to $8.9M from $19.4M.

• ·Inventory turnover declined to 3.4 from 3.7 (-8.1%).
• ·Average days’ sales in accounts receivable increased to 59 from 50 (+18%).
• ·Q4 2025 gross margin 22.8% vs 23.0% prior year.
• ·Ratio of working capital to sales improved to 28.8% from 25.1%.
• ·Net cash used in financing activities $16.3M vs $4.8M prior year.

03-03-2026

Angel Oak Mortgage REIT (AOMN) reported FY2025 net income allocable to common stockholders of $44M, up 53% YoY from $28.8M, with distributable earnings more than doubling to $14.6M from $7.0M, fueled by interest income growth of 30% to $143.7M and net interest income up 11% to $41.1M. Common stockholders' equity rose 12% to $267.5M, with book value per share increasing 6% to $10.74. However, economic book value per share declined 3% YoY to $12.70 amid mixed unrealized gains/losses, and realized losses persisted on RMBS ($2.3M) and CMBS ($0.6M).

• ·Residential portfolio weighted average: Interest rate 7.38%, FICO 760, CLTV 70.5%, DTI 32.4%, first lien 89.1%, 90+ days delinquent 0.4%.
• ·Commercial portfolio weighted average: Interest rate 7.40%, FICO 752, CLTV 71.7%, DTI 31.2%, first lien 96.7%, 90+ days delinquent 0%.
• ·Operating expenses declined to $16.4M from $19.4M YoY.
• ·Income tax expense fell to $0.5M from $3.3M YoY.

03-03-2026

Crexendo, Inc. reported FY2025 total revenue of $68.2M, up 12% YoY from $60.8M, with Software Solutions surging 27% to $29.7M while Cloud Telecommunications Services grew modestly 3% to $38.5M. Adjusted EBITDA rose 37% to $11.2M and net income increased to $5.1M from $1.7M. However, product revenue declined 16% to $4.7M and Cloud net dollar subscription retention fell to 98% from 100%.

• ·Annualized exit recurring revenue increased 12% to $57.5M as of Dec 31, 2025, with Cloud at $35.4M (+7%) and Software at $22.1M (+21%).
• ·Basic EPS $0.17 vs $0.06 YoY; Diluted EPS $0.16 vs $0.06.
• ·Income tax provision $300K in FY2025 vs $212K in FY2024.

03-03-2026

Twinlab Consolidated Holdings, Inc. (TLCC) reported net sales of $11.7M for the year ended December 31, 2024, down 14% YoY from $13.6M, contributing to a 22% decline in gross profit to $3.9M and a 28% wider operating loss of $1.8M. Selling expenses decreased 60% to $0.5M and interest expense improved 3%, while discontinued operations swung from a $4.1M loss to $0.3M income, resulting in total net loss improving 31% to $9.5M from $13.7M. General and administrative expenses remained flat at $5.2M YoY.

• ·Net loss per common share - basic and diluted: ($0.04) improved from ($0.05) YoY
• ·Sales channels include specialty retailers, health/natural foods, food/drug/mass market, direct-to-consumer websites, eTailers, and international distributors
• ·Filing date: March 03, 2026, covering year ended December 31, 2024

03-03-2026

Eagle Point Credit Company Inc. (ECCW) filed a DEFA14A definitive additional proxy material on March 3, 2026, as a reminder to shareholders to vote for the Special Meeting of Stockholders. The notice directs shareholders to contact proxy tabulator EQ Fund Solutions toll-free at (800) 848-3410 (9:00 am to 10:00 pm ET, Monday-Friday) using their Investor ID. It is signed by Courtney Fandrick, Secretary, from the company's Greenwich, CT office.

• ·Company address: 600 Steamboat Road, Suite 202, Greenwich, CT 06830

03-03-2026

Ascent Industries Co. (ACNT) reported net sales of $74.9M for 2025, down 7% YoY from $80.8M, but gross profit margin expanded significantly to 23.0% (+980 bps YoY) reaching $17.2M due to lower cost of goods sold. Operating loss from continuing operations narrowed to $(7.0)M from $(10.8)M, with net loss from continuing operations improving to $(5.6)M from $(12.6)M; however, overall net cash used in operating activities surged to $(7.3)M from $1.0M provided, and adjusted EBITDA remained negative at $(0.6)M despite improvement from $(4.7)M. Net income turned positive at $0.9M versus a $13.6M loss in 2024, driven by $6.5M gain from discontinued operations.

• ·Total assets decreased to $111.9M from $147.3M, primarily due to disposal of discontinued operations.
• ·Cash and cash equivalents increased to $57.6M from $16.1M.
• ·Shareholders' equity declined to $87.0M from $93.5M.
• ·Asset impairments recorded at $1.6M in 2025.
• ·Basic EPS from continuing operations improved to $(0.58) from $(1.24).

03-03-2026

Credo Technology Group Holding Ltd reported explosive Q3 revenue growth of 202% YoY to $407M and nine-month revenue surge of 237% YoY to $898M, with Q3 net income skyrocketing 435% to $157M and nine-month net income exploding to $303M from $16M. Gross margins improved to 68.5% from 63.6% YoY, while operating margins expanded to 37% from 19%. However, revenue concentration remains high with Customer A at 48% (down from 84%) and Customer B at 39%, and the company invested $83M in a business acquisition contributing to goodwill of $71M.

• ·Operating cash flow of $282M for 9M FY2026, up from $7M YoY
• ·Inventories increased to $208M from $90M balance sheet prior period
• ·Accounts receivable rose to $243M from $162M
• ·Share-based compensation $133M for 9M FY2026 vs $49M YoY
• ·Customer A concentration 53% for 9M FY2026 vs 66% prior

03-03-2026

Superior Group of Companies reported FY2025 consolidated net sales of $566.2M, up a marginal 0.1% YoY, with Branded Products growing 2.2% to $361.1M, but offset by declines in Healthcare Apparel (-2.8% to $115.9M) and Contact Centers (-4.6% to $92.5M). Gross margin fell 3.5% to $212.9M, leading to net income dropping 41.7% to $7.0M and EBITDA declining 24.5% to $25.7M, despite flat selling expenses and lower interest expense. Total assets increased to $421.8M, supported by higher cash and receivables, while shareholders' equity decreased to $192.8M amid share repurchases.

• ·Basic EPS declined to $0.47 from $0.75 YoY.
• ·Cash dividends per share remained flat at $0.56.
• ·Weighted average basic shares outstanding decreased to 14,966,139 from 16,008,015.
• ·Net cash from operating activities fell to $19.7M from $33.4M.
• ·Common shares repurchased: 938,144 in FY2025 vs. 523,472 in FY2024.
• ·Long-term growth rate assumption: 3.0%; Discount rate: 14.0% for BAMKO unit.

03-03-2026

First Business Financial Services, Inc. filed a Form S-3 shelf registration statement on March 3, 2026, enabling future offerings of various securities including common stock, preferred stock, debt securities, warrants, and units. The prospectus incorporates the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (filed February 25, 2026) and a Current Report on Form 8-K (filed February 2, 2026). Estimated expenses include an SEC registration fee of $13,810, with other costs to be determined.

• ·Financial statements as of December 31, 2025 and 2024, and for the three years ended December 31, 2025, audited by Crowe LLP.
• ·Legal matters to be passed upon by Godfrey & Kahn, S.C.
• ·Company headquarters: 401 Charmany Drive, Madison, Wisconsin 53719; Telephone: (608) 238-8008.
• ·Website: www.firstbusiness.com

03-03-2026

Evolus, Inc. reported total net revenues of $297.2M for the year ended December 31, 2025, up 11.6% YoY from $266.3M, primarily driven by product revenue growth to $295.0M from $264.3M. However, gross profit margin contracted to 66.3% from 68.5%, total operating expenses increased 6.0% to $229.8M, net loss widened slightly to $51.6M from $50.4M, and net cash used in operating activities deteriorated to $42.3M from $18.0M, resulting in cash and equivalents declining to $53.8M from $87.0M.

• ·Contingent royalty obligation terminates in Q2 2029; fair value revaluation resulted in $6.4M gain in 2025 vs $7.2M expense in 2024.
• ·Long-term term loan increased to $146.1M from $121.5M.
• ·Total assets declined to $225.9M from $232.6M; inventories rose to $27.0M from $12.2M.
• ·Restructuring costs of $1.4M incurred in 2025.

03-03-2026

Copart's Q3 FY26 total service revenues and vehicle sales declined 3.6% YoY to $1.12B, driven by a 4.0% drop in service revenues to $952M and 1.4% decrease in vehicle sales to $170M, resulting in operating income down 8.8% to $389M and net income attributable to Copart down 9.5% to $351M. For H1 FY26, total revenues fell 1.5% YoY to $2.28B with flat vehicle sales but service revenues down 1.7%, though net income attributable rose 0.7% to $754M amid higher interest income. Cash and equivalents surged 83% from July 2025 to $5.1B, boosted by $2.0B in securities proceeds, while the company repurchased $218M in shares.

• ·Operating cash flow for H1 FY26 was $663M, up slightly 0.4% YoY from $660M.
• ·Net cash from investing activities H1 FY26 was $1.86B, driven by $2.04B proceeds from held-to-maturity securities vs $1.13B prior year.
• ·Allowance for credit losses at Jan 31, 2026: $14.9M (up from $12.9M at Jul 31, 2025).

03-03-2026

Winning Catering Group, Inc. reported drastically reduced revenue of $21,290 for the year ended December 31, 2025, down 99.9% YoY from $16.8M in 2024, resulting in a net loss of $982K compared to a $6.7M profit prior year. Total assets plummeted to $5,912 from $38.8M, with most receivables and assets written down to zero, while operating cash flow shifted to a $1.2M use from $13.8M provided. However, the company received $2.0M repayment from a related party promissory note.

• ·Common stock authorized shares increased to 5,000,000,000 from 1,000,000,000.
• ·Cash Paid for Taxes in 2025: $160,000.
• ·Noncash Accrued Interest Income on Related Party Loan in 2025: $508,273.

03-03-2026

NeuroPace Inc (NPCE) reported FY2025 revenue growth of 25% YoY to $99.986M from $79.906M, with gross profit surging 31% to $77.220M driven by COGS increase of only 9%. However, operating expenses rose 16% to $93.558M, leading to an operating loss of $(16.338M) improved 25% from prior year, while net loss narrowed 21% to $(21.465M) from $(27.141M). Cash and equivalents ended at $21.692M after a net increase of $8.262M, supported by $19.600M from financing activities despite $11.006M cash burn in operations.

• ·Net loss per share improved to $(0.66) from $(0.93) YoY.
• ·Stock-based compensation expense increased to $11.089M from $10.282M.
• ·Long-term debt slightly decreased to $58.884M from $59.525M.
• ·Weighted-average shares used for EPS: 32,722,438 in 2025 vs 29,126,314 in 2024.

03-03-2026

CalciMedica, Inc. (Nasdaq: CALC) filed an S-3 shelf registration statement on March 3, 2026, to offer up to $125M in securities, including common stock, preferred stock, debt securities, and warrants, for general corporate purposes such as R&D and clinical trials. The company qualifies as an emerging growth company with reduced disclosures while public float remains below $250M (or $700M with revenue under $100M). No immediate sales are occurring, and investors are directed to review incorporated risk factors from recent 10-K and 10-Q filings.

• ·Originally formed as Graybug, LLC in May 2011; converted to corporation in February 2015.
• ·Merger completed March 20, 2023 per agreement dated November 21, 2022 (amended February 10, 2023); Private CalciMedica dissolved December 31, 2024.
• ·Corporate headquarters: 505 Coast Boulevard South, Suite 307, La Jolla, CA 92037.

03-03-2026

Advantage Solutions Inc. (ADV) reported FY2025 revenues of $3.54B, down 0.7% YoY from $3.57B, driven by 10.8% growth in Experiential Services to $1.44B but offset by 10.9% decline in Branded Services to $1.16B and 2.2% drop in Retailer Services to $0.94B. Operating loss from continuing operations improved 57.1% to $126.5M from $295.0M, primarily due to lower goodwill impairments ($203.7M vs $275.2M), while net loss narrowed 39.8% to $227.7M; however, Adjusted EBITDA declined 6.8% to $331.8M, with Branded Services down 21.2% and Retailer Services down 11.6%, despite 34.1% growth in Experiential Services. Adjusted Net Income fell 18.7% to $61.6M YoY.

• ·Filing date: March 03, 2026 for year ended December 31, 2025
• ·Cost of revenues: 86.0% of revenues in 2025 (down from 85.8%)
• ·Selling, general, and administrative expenses: down to 7.8% of revenues from 9.1%
• ·Interest expense, net: $138.9M in 2025 (down from $146.8M)
• ·Adjusted EBITDA margin: 9.4% in 2025 (down from 10.0%)

03-03-2026

Hyperscale Data, Inc. filed a DEF 14A proxy statement seeking shareholder approval for an amendment to its Certificate of Incorporation to authorize a reverse stock split of Class A Common Stock at a Board-determined ratio between 1-for-2 and 1-for-5, effective at any time prior to March 17, 2027. The proposal aims to increase the per-share price to meet NYSE American continued listing requirements due to persistently low share prices and enhance attractiveness to institutional investors, though no assurance of post-split price increase is given. Approximately 343 million shares of Class A Common Stock are outstanding as of the record date.

• ·Reverse stock split, if implemented, effective upon filing certificate of amendment with Delaware Secretary of State; Board may abandon if not in best interests.
• ·Record date not specified in excerpt; meeting implied around March 18, 2026.
• ·Cash payment in lieu of fractional shares; new CUSIP number post-split; trading symbol remains GPUS.
• ·Former names: Ault Alliance, Inc. (name change Jan 3, 2023), BitNile Holdings, Inc. (Dec 13, 2021), Ault Global Holdings, Inc. (Jan 19, 2021).

03-03-2026

Kadant Inc reported flat consolidated revenue of $1.05B for FY ended January 3, 2026 versus prior year, with organic revenue declining 4% due to a 12% drop in Industrial Processing despite 3% organic growth in Material Handling and flat Flow Control. Operating income rose 8% to $302M, lifting margins to 28.7% from 26.6%, but net income fell to $102M from $112M and adjusted EBITDA decreased to $216M (20.6% margin) from $230M (21.8%).

• ·Corporate operating expenses increased 8% to $44.5M.
• ·Interest expense, net declined to $13.6M from $18.1M.
• ·Adjusted EBITDA for FY ended Dec 30, 2023 was $201M (21.0% margin).

03-03-2026

Horizon Technology Finance Corp's 10-K details its investment strategy focused on secured Venture Loans to development-stage companies in target industries, utilizing collateral, current-pay interest, amortization, and warrants for lower-risk returns compared to equity investments. The filing describes an internal portfolio rating system from 1 (high risk of principal loss, non-accrual) to 4 (lowest risk, exceeding expectations). It discloses the Advisor received $6.4 million in cumulative aggregate capital gains fees, potentially exceeding a $5 million threshold based on 20% of $25 million net realized gains/losses or unrealized depreciation, with no period-over-period financial metrics provided.

• ·Portfolio loans rated 4: lowest risk, exceeding expectations with no principal loss expected.
• ·Portfolio loans rated 3: standard risk, meeting expectations with no principal loss expected.
• ·Portfolio loans rated 2: increased risk, below expectations with potential for future principal loss.
• ·Portfolio loans rated 1: high risk, well below plan, typically non-accrual with high degree of principal loss risk.
• ·Failure to qualify as RIC under Subchapter M would subject company to corporate-level U.S. federal income tax on all income, materially adversely affecting financial performance.

03-03-2026

HYSTER-YALE, INC. reported FY 2025 revenues of $3,769.3M, down 12.5% YoY from $4,308.2M, with declines across segments including Americas (-12.6%), EMEA (-19.5%), and Bolzoni (-12.1%), while JAPIC was essentially flat (-0.1%). The company swung to a net loss of $60.1M from $142.3M profit in 2024, with operating loss of $22.1M versus $244.8M profit, primarily due to lower unit volumes and gross profit margins; however, bookings improved to $1,840M from $1,670M and SG&A expenses rose only 1.8%. Backlog decreased to $1,280M at year-end from $1,930M.

• ·Gross profit declined 29.3% to $632.8M from $895.5M, with EMEA gross profit down 50.0%.
• ·Restructuring and impairment charges decreased 69.9% to $38.4M from $22.6M.
• ·Interest expense improved 7.7% to $31.2M from $33.8M.
• ·Americas truck volumes declined, especially higher-value core counterbalanced trucks.

03-03-2026

Versant Media Group, Inc. reported revenue of $6.688B for the year ended December 31, 2025, down 5.3% YoY from $7.062B in 2024, driven by declines in Linear distribution (-5.4%), Advertising (-8.9%), and Content licensing (-8.5%), though Platforms grew 3.9%. Operating income fell sharply 30.9% to $1.272B and net income attributable to Versant dropped 31.8% to $930M, with Adjusted EBITDA declining 14.5% to $2.425B. Cash from operating activities remained solid at $2.022B, supporting a cash position increase to $55M plus $1.034B restricted cash, despite new long-term debt of $983M.

• ·Selling, general and administrative expenses rose 25.9% YoY to $1.469B in 2025.
• ·Cash used in investing activities increased to $155M in 2025 from $71M in 2024.
• ·Cash used in financing activities decreased to $782M in 2025 from $2.155B in 2024.
• ·No long-term debt in 2024; $983M as of Dec 31, 2025.
• ·Filing date: March 03, 2026 for year ended December 31, 2025.

03-03-2026

Arcturus Therapeutics reported total revenue of $82M for 2025, down 46% YoY from $152M, primarily due to a 51% drop in collaboration revenue to $67M, though grant revenue increased 6% to $15M. Operating expenses fell 36% YoY to $158M, with R&D expenses declining 43% to $112M and G&A down 13% to $46M, narrowing the net loss to $66M from $81M. Cash and equivalents decreased slightly to $231M from $237M, with net cash used in operations rising to $74M from $60M.

• ·Total assets decreased to $271M from $344M as of Dec 31, 2025 vs 2024.
• ·Accumulated deficit increased to $(515M) from $(449M).
• ·Interest income declined 34% YoY to $10M.
• ·Financing activities provided $13M in 2025 vs $5M in 2024.
• ·Restricted cash: $0 current in 2025 vs $55M in 2024.

03-03-2026

Quantum-Si Inc reported FY2025 total revenue of $2.4M, down 20.3% YoY from $3.1M, driven by a 21.8% decline in product revenue to $2.3M despite 12.8% growth in service revenue to $0.15M; gross profit fell 27.9% to $1.2M. Operating expenses increased 6.4% to $117.3M due to one-time lease termination expense of $13.6M and legal settlement expense of $5.2M, resulting in operational loss widening 6.9% to $116.1M and net loss slightly up 0.3% to $101.3M. Cash and equivalents dropped to $21.6M from $49.2M amid $94.7M used in operations, partially offset by $95.4M from equity financing.

• ·Stockholders’ equity increased to $220.2M from $215.4M, driven by $93.5M net proceeds from direct equity offerings.
• ·Marketable securities totaled $194.1M as of Dec 31, 2025 (current $141.3M, non-current $52.9M) vs $160.4M prior year.
• ·Accumulated deficit grew to $698.0M from $596.6M.
• ·Class A shares issued and outstanding rose to 196.4M from 147.0M.

03-03-2026

KKR Real Estate Finance Trust Inc. (KREF-PA) filed a DEFA14A Definitive Additional Proxy Materials on March 03, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No substantive proxy details, financial data, or voting matters are disclosed in the provided content.

03-03-2026

03-03-2026

Accel Entertainment's total net revenues rose 8.1% YoY to $1.33B in 2025 from $1.23B in 2024, fueled by Louisiana's explosive 590% growth to $37.6M, Nebraska +30.9%, Georgia +50.6%, and Illinois +6.2%, though Nevada declined 4.9%, Montana grew only 1.6%, amusement revenues fell 2.5%, and manufacturing dropped 11.3%. Net income increased 45.3% to $51.3M, operating income rose 18.7% to $107.9M, and Adjusted EBITDA climbed 11.1% to $210.1M. Operating cash flow improved 24.5% to $150.9M, supported by expansions in new markets like Fairmount Park in Illinois and Toucan Gaming in Louisiana.

• ·Operations in Illinois started 2012; Fairmount Park acquired 2024 with 57 racing days planned for 2026 and ~260 gaming positions.
• ·Montana operations via Century Gaming and Grand Vision Gaming started 2022; Yellowstone Casino added 2023 with five parlor locations.
• ·Nevada via Century Gaming started 2022; Nebraska via Accel Entertainment started 2022.
• ·Georgia via Bulldog Gaming started 2020; Louisiana via Toucan Gaming started 2024.
• ·Iowa started 2021; Pennsylvania started 2023, actively exploring truck stops.
• ·Statutory splits in Illinois, Georgia, Pennsylvania; negotiated splits in Montana, Nevada, Nebraska, Iowa, Louisiana.

03-03-2026

Ambev's 20-F annual report provides macroeconomic data showing Brazil's GDP growth slowing to 2.4% in 2025 (nine months) from 3.4% in 2024, with unemployment improving to 5.1% from 6.8% and IGP-M inflation turning deflationary at -1.1% from 6.5%; however, IPCA inflation edged down only slightly to 4.3% from 4.8%. In Argentina, GDP rebounded strongly to 5.2% growth from -1.7%, unemployment fell to 6.6% from 8.2%, and inflation declined sharply with CPI at 31.5% versus 117.8% and wholesale IPIM at 26.2% from 67.1%. The report also discusses inflation mitigation strategies including price adjustments and inflation-linked contracts for packaging and malt.

• ·Brazil closing exchange rate: 5.5024 BRL/USD (2025) vs 6.1923 (2024), indicating real appreciation.
• ·Brazil average exchange rate: 5.5879 BRL/USD (2025) vs 5.3895 (2024).
• ·Argentina average exchange rate: ARS 1455 per USD (2025) vs ARS 916.75 (2024).

03-03-2026

Revenue surged 95,917% YoY to $17.3M in 2025 from $18k in 2024, driven by non-licensing revenue of $9.5M (+52,700%) and new licensing revenue of $7.8M, resulting in gross profit of $10.2M versus a $71k loss. However, operating expenses ballooned to $42.5M including $34.1M SG&A (+375%) and $8.5M asset impairment, widening the operating loss to $32.3M from $5.1M. Net loss narrowed to $33.3M from $41.7M, supported by a $1.5M gain from discontinued operations including disposal of the Extraction business, though cash used in operations increased to $23.5M.

• ·Weighted average shares outstanding increased to 1,993,947 in 2025 from 1,020,185 in 2024.
• ·Net cash used in investing activities was $55.1M in 2025 versus $54k in 2024.
• ·Income tax provision was $0 in 2025 versus $2k in 2024.
• ·Loss per share improved to $(16.68) from $(40.92).

03-03-2026

AnaptysBio's collaboration revenue surged 157% YoY to $234.6M in 2025 from $91.3M in 2024, driven by $75M in GSK milestones, doubled Jemperli royalties to $95.9M, and new Vanda revenue of $9.7M. However, the company reported a net loss of $13.2M, an improvement from $145.2M but still negative, with R&D expenses down 17% to $136M offset by 20% higher G&A at $50.7M; total assets declined 25% to $364M amid sharp drops in investments. Cash and equivalents rose to $238M with positive operating cash flow of $19.7M versus prior cash burn.

• ·PD-1/Jemperli milestones: $258M recognized through 2025, $15M potential future.
• ·GPP-related future milestones: $35M potential (none recognized).
• ·Operating cash flow turned positive at $19.7M in 2025 from -$135.3M in 2024.
• ·Repurchased 3,444 thousand common shares in 2025 for $69M.
• ·Liability related to sale of future royalties: $276.5M at Dec 31, 2025 (down from $353.4M).

03-03-2026

United Parks & Resorts Inc. (PRKS) reported FY2025 total revenues of $1.66B, down 3.6% YoY from $1.73B, driven by a 6.0% decline in admissions to $883M and a 0.8% drop in food, merchandise, and other to $779M, while attendance fell 1.8% to 21.2M. Operating income decreased 21.1% to $365M and net income dropped 26.0% to $168M; however, in-park per capita spending rose 1.0% to $36.81, interest expense fell 20.0% to $134M, and Adjusted EBITDA was $605M despite the revenue decline.

• ·Capital expenditures totaled $217M in FY2025, down from $248M in 2024, with core capex at $182M.
• ·Total contractual obligations as of Dec 31, 2025: $3.38B, including $2.25B long-term debt.
• ·Stockholders’ deficit improved to $(436)M from $(462)M YoY.
• ·Property and equipment, net: $1.92B as of Dec 31, 2025, up from $1.89B.

03-03-2026

ABVC BioPharma's 10-K filing discloses a restatement of its September 30, 2025 interim financials, eliminating $795,950 in previously reported revenue for both Q3 and 9M periods, which worsens Q3 net loss from $(1.3M) or $(0.05) per share to $(2.1M) or $(0.09) per share, and 9M net loss from $(4.6M) or $(0.23) per share to $(5.4M) or $(0.28) per share. The restatement also adjusts accumulated deficit deeper by $795,950 and reduces due from related parties by $760,546, though property and equipment net increases by $798,486. Historical BHK collaboration provided $2M in milestone payments (2015-2016) with 12% royalties pending, but no royalties earned as of December 31, 2022, and phase II trial for ABV-1505 ADHD remains incomplete.

• ·Phase II clinical trial for ABV-1504 MDD completed October 31, 2019; phase II for ABV-1505 ADHD not completed as of December 31, 2022.
• ·No royalties earned under BHK agreement as of December 31, 2022.
• ·Filing highlights risks including share price volatility, shareholder influence, future stock issuances, and litigation costs.

03-03-2026

OFG Bancorp's definitive proxy statement, filed March 3, 2026, solicits votes for its virtual annual shareholder meeting on April 22, 2026, including the election of nine directors for a one-year term, an advisory vote on executive compensation, and ratification of the independent registered public accounting firm for 2026. The record date is March 2, 2026, with 42,477,261 shares of common stock outstanding, and the Board recommends voting 'FOR' all proposals. No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Virtual annual meeting at 10:00 a.m. (AST) on April 22, 2026 at www.virtualshareholdermeeting.com/OFG2026
• ·Proxy votes must be received by close of business on April 21, 2026
• ·Cumulative voting permitted for election of nine directors
• ·Proxy materials made available on or about March 3, 2026

03-03-2026

Fortitude Gold Corp reported a sharp 63.5% YoY decline in gold ounces sold to 5,774 oz in 2025 from 15,825 oz in 2024, leading to lower total cash costs after by-product credits at $6.4M vs $13.1M and total all-in sustaining costs at $9.8M vs $15.3M. However, all-in sustaining costs per ounce sold surged 75.7% to $1,697 from $966, driven by higher sustaining capital expenditures ($1.8M vs $0.6M) while sustaining exploration expenses remained flat at ~$1.6M. By-product credits from silver sales also declined 25% to $1.3M from $1.7M.

• ·Total cash cost before by-product credits: $7.6M in 2025 vs $14.8M in 2024
• ·Depreciation and amortization: $2.2M in 2025 vs $5.9M in 2024
• ·Treatment and refining charges: $0.3M in 2025 vs $0.2M in 2024
• ·Reclamation and remediation: $0.2M in 2025 vs $0.2M in 2024

03-03-2026

Civeo Corp's 2025 total revenue declined 6.3% YoY to $639M from $682M, primarily due to a 27.2% drop in Canada revenues to $179M amid a 29.7% reduction in billed rooms, while Australia revenues grew 7.8% to $460M supported by 10.3% higher billed rooms and stable ADRs. Operating income improved 109% to $4.1M from $1.3M with no impairment charges, but net loss attributable to Civeo widened 17.6% to $20.1M from $17.1M due to higher interest expense and income taxes. Available liquidity fell sharply to $90M from $202M.

• ·Australia ADR flat at $76 (down $2 YoY), Canada ADR flat at $97.
• ·Impairment expense $0 in 2025 vs $11.6M in 2024.
• ·Basic EPS loss $(1.59) in 2025 vs $(1.19) in 2024.
• ·Lender commitments increased to $265M from $245M as of Dec 31 2025.

03-03-2026

Darling Ingredients reported FY2025 total net sales of $6.14B, up 7.4% YoY from $5.72B, with growth across segments including Feed Ingredients +8.6% to $3.99B, Food Ingredients +3.7% to $1.55B, and Fuel Ingredients +9.2% to $601M; gross margin improved to 24.0% from 22.4%. However, net income attributable to Darling sharply declined 77.5% YoY to $62.8M from $279M, driven by a swing to a $48.8M equity loss from Diamond Green Diesel (vs $149M income prior year), higher restructuring charges of $58M (vs $5.8M), and lower operating income of $273M (down 41.6%). Adjusted EBITDA rose 16.8% to $923M, providing some offset.

• ·Restructuring and asset impairment charges increased to $58.0M in FY2025 from $5.8M in FY2024.
• ·Long-term debt decreased slightly to $3.86B as of Jan 3, 2026 from $3.91B as of Dec 28, 2024.
• ·Investment in unconsolidated subsidiaries $2.21B as of Jan 3, 2026 vs $2.26B prior year.
• ·Diluted EPS $0.39 in FY2025 vs $1.73 in FY2024.
• ·Total sales to Diamond Green Diesel $1.20B in FY2025 vs $969M in FY2024.

03-03-2026

Agilent Technologies reported net revenue of $1.8B for the three months ended January 31, 2026, up 7% YoY from $1.7B, with products revenue increasing 6% to $1.3B and services up 9% to $525M. However, operating income declined 6% to $353M due to higher total costs (+9%) and SG&A expenses surging 16% to $476M, leading to net income of $305M, down 4% YoY. Operating cash flow also fell sharply 38% to $268M from $431M YoY.

• ·Diluted EPS of $1.07, down 3.6% YoY from $1.11.
• ·Total current assets $4,615M as of Jan 31, 2026, up slightly QoQ from $4,594M.
• ·Long-term debt steady at $3,050M QoQ.
• ·Cash dividends declared at $0.255 per share ($72M total) vs $0.248 per share ($71M) prior year.
• ·Income taxes paid $105M vs $19M YoY.

03-03-2026

AES Corporation filed DEFA14A additional proxy materials on March 3, 2026, referencing a press release issued on March 2, 2026, announcing an undisclosed transaction. The filing indicates that a full proxy statement will be provided to AES stockholders in connection with the transaction. No financial details or performance metrics were disclosed in the filing.

• ·Filing Type: DEFA14A (Definitive Additional Proxy Materials)
• ·Subcategory: Proxy Statement

03-03-2026

Enliven Therapeutics reported a widened net loss of $103.7M for 2025, up 16.5% YoY from $89.0M in 2024, driven by total operating expenses rising 14.4% to $119.7M with R&D up 6.2% to $85.9M and G&A surging 42.1% to $33.8M. While net cash used in operations improved slightly by 4.0% to $70.3M and financing activities provided $218.9M (up 64.3% YoY), overall cash and equivalents declined $25.3M to $98.9M; however, total liquidity including marketable securities increased to $462.6M from $313.4M, boosting stockholders' equity to $459.6M from $309.8M. Net loss per share improved marginally to ($1.83) from ($1.89) on higher share count.

• ·Public offering net proceeds of $216.2M in 2025; prior private placement $89.7M in 2024.
• ·Stock-based compensation expense $34.0M in 2025 vs $20.2M in 2024.
• ·Accumulated deficit grew to $347.2M from $243.5M.
• ·All marketable securities and cash equivalents are Level 1 fair value (U.S. Treasury securities).

03-03-2026

Sana Biotechnology reported a narrowed net loss of $244.2M for the year ended December 31, 2025, improving 8.5% YoY from $266.8M in 2024, driven by sharp reductions in R&D expenses (down 38.8% to $132.0M) and G&A (down 30.8% to $44.3M), with total operating expenses decreasing 8.2% to $250.3M. However, a massive $44.6M impairment of long-lived assets (up over 2,260% from $1.9M) contributed to declines in cash and cash equivalents to $71.9M (down 43.6%) and stockholders' equity to $160.9M (down 35.8%), while cash used in operating activities improved to $143.8M from $223.2M.

• ·Net loss per share improved to $(0.96) in 2025 from $(1.16) in 2024.
• ·Raised $45.8M net from at-the-market offering and $80.6M from common stock financings in 2025.
• ·Total assets declined to $416.9M as of Dec 31, 2025 from $501.0M.
• ·Contingent consideration totaled $123.7M as of Dec 31, 2025 (up from $108.9M).

03-03-2026

Upland Software, Inc. reported FY2025 total revenue of $217M, down 21% YoY from $275M in 2024 and 27% from $298M in 2023, driven by a 21% decline in subscription and support revenue to $205M. Gross profit declined 16% to $162M but margins improved to 75% from 70%, enabling operating income of $4.4M versus a $102M loss in 2024; however, net loss narrowed to $39M from $113M amid lower impairments but offset by a $24M loss on divestitures and 77% higher interest expense to $16M. All major revenue segments declined 10-21% YoY with no growth areas.

• ·Professional services revenue declined 21% YoY to $6.5M (flat 3% of total revenue).
• ·Sales and marketing expenses down 33% YoY to $44M.
• ·Depreciation and amortization down 41% to $27M.
• ·Loss per common share improved to ($1.56) from ($4.26).

03-03-2026

SOPHiA GENETICS SA filed an F-3 shelf registration statement on March 3, 2026, to register up to 75,000 ordinary shares for resale by a selling shareholder upon exercise of a Second Amendment warrant certificate. The company will not receive proceeds from the resale but may receive up to $388,717.50 if the warrant is fully exercised, to be used for working capital and general corporate purposes. As of December 31, 2025, the company's share capital stood at CHF 4,466,061, with 89,321,220 ordinary shares outstanding.

• ·Share capital increases: June 26, 2023 (+10,500,000 shares), June 24, 2024 (+2,423,056 shares), Nov 5, 2025 (+10,000,000 shares).
• ·Board authorized under capital range to increase share capital up to CHF 4,979,862.30 (max 33,199,082 shares) until June 18, 2030, with ability to limit pre-emptive rights.
• ·No cash dividends paid or anticipated; restricted by Perceptive Credit Agreement.

03-03-2026

Hinge Health reported revenue of $588M for the year ended December 31, 2025, up 51% YoY from $390M in 2024, driven by expansion in contracted clients, with gross profit increasing 56% to $468M and gross margin improving to 80% from 77%. However, operating expenses surged over 200% to $1.0B, with R&D up to 63% of revenue, sales & marketing up 90%, and G&A more than quintupling, leading to an operating loss widening to $546M from $32M and net loss ballooning to $528M from $12M. Stock-based compensation exploded to $643M, representing the bulk of expense increases.

• ·Cost of revenue as % of revenue improved to 20% in 2025 from 23% in 2024 and 34% in 2023.
• ·Other income, net declined to 3% of revenue in 2025 from 5% in 2024.
• ·Stock-based compensation in R&D was $265M in 2025 vs $202k in 2024.

03-03-2026

Super Micro Computer, Inc. (SMCI) filed a DEFA14A Definitive Additional Proxy Materials on March 03, 2026, marked as a proxy supplement for FY2025. The filing contains only standard header information with no specific proposals, board matters, or shareholder actions detailed. No quantitative financial data or performance metrics are disclosed.

• ·Filing classified as Definitive Additional Materials under Schedule 14A.

03-03-2026

Silicon Labs filed a DEFA14A additional proxy statement on March 3, 2026, referencing prior SEC filings for details on directors, executive officers, security ownership, and governance in connection with a proposed merger transaction with Texas Instruments. The document provides access to relevant 10-Ks, proxies, and Forms 3/4/5 via SEC and company websites, while cautioning that no offer or solicitation is being made. It includes extensive forward-looking statement disclaimers highlighting risks such as failure to secure stockholder or regulatory approvals, business disruptions, stock price declines if the deal fails, and operational limitations under the merger agreement.

• ·Silicon Labs FY ended January 3, 2026 (10-K filed February 10, 2026)
• ·Texas Instruments FY ended December 31, 2025 (10-K filed February 6, 2026)
• ·Silicon Labs 2025 proxy filed March 12, 2025
• ·Texas Instruments 2025 proxy filed March 5, 2025

03-03-2026

Caris Life Sciences reported total revenue of $812M for the year ended December 31, 2025, surging 97% YoY from $412M in 2024, primarily driven by molecular profiling services which grew 119.6% to $767M. However, pharma research and development services declined 28.2% to $45M, operating expenses as a percentage of revenue improved but remained high at 94%, and the company recorded a net loss of $68M (improved from $282M) amid a sharp negative swing in changes in fair value of financial instruments.

• ·Molecular profiling revenue growth driven by MI Profile volume (+$52M) and ASP increase (+$311M), plus Caris Assure (+$54M).
• ·Total costs and operating expenses $767M in 2025 (94% of revenue) vs $669M in 2024 (162% of revenue).
• ·Net cash from financing activities $665M in 2025 vs $200M in 2024.
• ·Depreciation and amortization $23M in 2025 (down from $49M); stock-based compensation $70M (up from $19M).

03-03-2026

James River Group Holdings, Inc. reported a net income turnaround to $47.4M in 2025 from an $81.1M loss in 2024, with underwriting profit swinging to $20.3M from a $105.6M loss and combined ratio improving to 96.6% from 117.6%, led by Excess and Surplus Lines profit of $59.5M versus a $77.5M loss. However, gross written premiums declined 18.1% YoY to $1.17B, net written premiums fell 2.1% to $569M, net earned premiums remained flat at $600M, and net investment income dropped 10.4% to $83.4M. Shareholders’ equity rose 16.7% to $538M, while tangible common equity increased to $411M from $305M.

• ·Cash used in operating activities (excluding restricted cash): $1.4M in 2025 vs ($203M) in 2024.
• ·Change in cash, cash equivalents, and restricted cash equivalents: ($122M) in 2025 vs $31M in 2024.
• ·Reserve for losses and loss adjustment expenses payments: $3.1B total, with $840M due in 2026.
• ·Senior debt: $226M total, $211M due 2027-2028.
• ·Junior subordinated debt: $104M due thereafter.
• ·Adjusted net operating income: $54.1M in 2025 vs ($41.5M) loss in 2024.

03-03-2026

Immunome Inc. (IMNM) reported a narrowed net loss of $212.4M for the year ended December 31, 2025, improved from $293.0M in 2024, primarily due to a sharp drop in in-process R&D expenses to $10.0M from $152.3M and total operating expenses declining 27% YoY to $231.1M. However, collaboration revenue fell 23% to $6.9M, R&D expenses increased 37% to $177.3M amid higher ongoing activities, G&A rose 33% to $43.8M, and cash used in operations worsened to $190.9M from $110.8M. The company's cash position strengthened significantly to $653.5M, driven by $640.4M in financing activities, boosting total assets to $683.2M.

• ·Auditor identified accrued and prepaid R&D expenses as a critical audit matter due to judgment in estimating progress of third-party vendor services.
• ·Common shares outstanding increased to 113.1M from 64.5M, reflecting dilution from financing.
• ·Net loss per share improved to $(2.43) from $(5.00), with weighted-average shares of 87.4M vs 58.6M.

03-03-2026

Teucrium Commodity Trust filed an S-1/A registration statement on March 03, 2026, detailing methodologies for three Carbon Credit Futures Sub-indexes (European EUA, California Carbon Allowance, RGGI CO2) administered by Solactive AG, each with a start date of January 16, 2024, at an initial level of 100, featuring a five-day roll period offset by 15 trading days. The filing also describes Bitcoin valuation using median time-weighted average prices from 3:00-4:00 pm ET across five approved platforms (Bitstamp, Crypto.com, Gemini, itBit, Kraken), which must meet criteria including a $30M minimum monthly volume threshold. No financial performance metrics, period-over-period comparisons, or operational results are disclosed.

• ·Sub-indexes calculated daily using settlement levels from ICE Futures U.S.; European from 8:00-19:00 CET, others 3:00-16:00 ET.
• ·Roll Period: 5 trading days starting 15 days before active contract expiry; weights shift 20% per day.
• ·Bitcoin pricing sources reviewed twice yearly by Kaiko; must have 2+ years history, comply with AML/KYC, no sanctions jurisdictions.
• ·Index Pricing Sources as of filing: Bitstamp (Luxembourg), Crypto.com (Singapore), Gemini (USA/Ireland), itBit (USA), Kraken (USA/UK).

03-03-2026

Century Aluminum reported net sales of $2.53B for 2025, up 14% YoY from $2.22B in 2024, with gross profit rising 49% to $256.4M driven by higher sales to other customers and primary aluminum revenue increasing 18% to $2.20B despite a 5% decline in total shipments to 647K tonnes. However, net income attributable to stockholders fell sharply 88% to $41.8M from $336.8M due to a $94.7M loss on derivative contracts and absence of 2024's $245.9M bargain purchase gain, while operating cash flow improved dramatically to $185.0M from a $24.6M outflow.

• ·US primary aluminum shipments declined 1.7% YoY to 371,708 tonnes while revenue rose 31% to $1.41B.
• ·Iceland primary aluminum shipments fell 8.2% YoY to 275,404 tonnes with revenue down 1% to $785.6M.
• ·Sales to related parties increased 4% YoY to $1.37B, representing 54% of total net sales.
• ·Current assets grew 56% to $646.0M as of Dec 31, 2025.
• ·Basic EPS declined to $0.42 from $3.44 YoY.

03-03-2026

Cellebrite DI Ltd. reported FY 2025 revenue of $476M, up 19% YoY from $401M, driven by 22% growth in subscription services to $331M and 17% in term-license to $96M, while other non-recurring revenue grew just 3% and professional services remained flat at $31M. ARR increased 21% YoY to $481M, though growth slowed from 25% prior year and dollar-based net retention rate declined to 116% from 124%. Adjusted EBITDA rose 28% to $128M with margin expansion to 27%, free cash flow increased to $160M (34% margin), and the company achieved net income of $78M versus a $283M loss in 2024.

• ·Financial income (expense), net improved to income of $24M from expense of $333M YoY.
• ·Cost of revenue increased 20% YoY to $75M, with cost of subscription services up 44%.
• ·Total operating expenses rose to $334M from $282M, driven by higher R&D (+16%), sales & marketing (+17%), and G&A (+28%).

03-03-2026

Autodesk, Inc. reported net revenue of $7,206M for FY26 ended January 31, 2026, up 18% YoY from $6,131M in FY25, driven by strong growth in subscription revenue (+18% to $6,743M) and AECO product family (+22% to $3,583M). Recurring revenue increased 18% to $7,024M, representing 97% of net revenue, with RPO rising to $8,300M. However, maintenance revenue declined 20% to $33M, M&E grew only 5% to $332M, and APAC revenue increased at a slower 11% to $1,234M.

• ·Deferred revenue increased to $4,693M as of Jan 31, 2026 from $4,128M prior year.
• ·Unbilled deferred revenue rose to $3,607M from $2,810M.
• ·EMEA revenue grew 21% YoY to $2,794M in FY26.
• ·Americas revenue up 17% to $3,178M in FY26; U.S. +15% to $2,566M.
• ·FY25 net revenue grew 12% YoY from $5,497M in FY24.

03-03-2026

TransCode Therapeutics, Inc. (RNAZ) entered into an Exclusive Licensing Agreement with Unleash Immuno Oncolytics, Inc. on March 2, 2026, acquiring exclusive worldwide rights to a pre-clinical genetically-engineered adenovirus program for cancer immunotherapy in exchange for 1,136,364 shares of Series C Non-Voting Convertible Preferred Stock. The company also issued 77,841 Series C shares to Tungsten Advisors as financial advisory compensation. The preferred shares are non-voting, rank parity with common stock on liquidation, and convertible to common stock only after stockholder approval, subject to a 4.99% beneficial ownership limitation.

• ·Certificate of Designation filed with Delaware Secretary of State on March 2, 2026.
• ·Series C Preferred Stock has no dividend rights and no voting rights except on specific protective provisions.
• ·Company confirmed as emerging growth company; common stock trades on Nasdaq Capital Market (RNAZ).

03-03-2026

Rigel Pharmaceuticals reported total revenues of $294.3M for FY 2025, up 64% YoY from $179.3M, driven by product sales net growth of 60% to $232.0M and collaboration revenues up 81% to $62.0M. However, collaboration revenues showed declines from Kissei (-65% to $7.2M) and Dr. Reddy's (-98% to $0.1M), cost of product sales rose slightly by 5%, and net cash decreased by $16.1M compared to a $24.0M increase in 2024. A significant tax benefit of $245.2M was recorded in 2025.

• ·Net cash from operating activities: $75.7M in FY2025 (up from $31.5M in FY2024).
• ·Net cash used in investing activities: $92.4M in FY2025 (vs. $4.1M provided in FY2024).
• ·Interest income: $3.7M in FY2025 (up from $2.1M).
• ·Interest expense: $7.3M in FY2025 (down from $7.9M).

03-03-2026

iSpecimen Inc. filed a DEFA14A amendment to its proxy statement originally filed on February 17, 2026, announcing Ms. Siyun Yang's resignation from the Board of Directors and her removal as a nominee for election at the Annual Meeting. Proposal No. 1 now provides for the election of only the remaining nominees, with the Board intending for them to stand for election as previously described. Existing proxy votes for Proposal No. 1 will apply solely to the remaining nominees without requiring further action from shareholders.

• ·Amendment filed March 03, 2026
• ·Original proxy statement filed February 17, 2026

03-03-2026

Anheuser-Busch InBev SA/NV's 2025 annual revenue totaled $59.32B, down 0.7% YoY from $59.77B in 2024, reflecting growth in EMEA (+5.6%) and Middle Americas (+1.8%) but declines in North America (-3.0%), South America (-3.8%), and Asia Pacific (-8.1%). Regional revenue shares shifted, with North America dropping to 24.0% from 24.5% and Asia Pacific to 9.6% from 10.4%. The filing highlights ongoing risks including anti-corruption compliance, cybersecurity threats, and potential equity dilution.

• ·Revenue defined as turnover less excise taxes and discounts.
• ·2023 total revenue was $59.38B, up 0.7% from 2023 to 2024.

03-03-2026

Paysafe Ltd reported FY2025 revenue of $1.70B, down 0.2% YoY from $1.70B amid a 5.5% decline in one segment offset by 6.4% growth in another, while operating income fell 46.1% to $72M due to elevated restructuring costs of $48M (up 834%) and other expenses. This resulted in a net loss of $183M versus a $22M profit in FY2024, with Adjusted EBITDA declining to $429M from $452M. Balance sheet remained stable at $4.8B total assets, with cash up to $250M but non-current debt rising to $2.61B.

• ·Share-based compensation expense: $32M in FY2025 vs $39M in FY2024.
• ·Income tax expense: $110M in FY2025 vs benefit of $8M in FY2024.
• ·Treasury shares increased to 12M shares in FY2025 from 2.6M in FY2024.
• ·Goodwill increased to $2.08B as of Dec 31, 2025 from $1.98B as of Dec 31, 2024.

03-03-2026

STAAR Surgical Co reported FY2025 net sales of $239.4M, down 23.7% YoY from $313.9M in FY2024 (itself down 2.6% from $322.4M in FY2023), with sales to China distributors plummeting 52% to $77.8M (32.5% of total vs 51.7% prior year). While gross profit margin held nearly flat at 76.2% and absolute G&A, S&M, and R&D expenses declined 4.6%, 12.4%, and 11.6% YoY respectively, these rose sharply as percentages of sales (to 35.8%, 42.8%, 16.7%), compounded by 7.2% merger costs and 12.0% restructuring charges, resulting in operating loss widening to -38.3% and net loss margin to -33.6% from -6.6%. No share repurchases occurred despite $23.5M remaining authorization.

• ·No shares repurchased in Q4 FY2025 periods despite $23.5M authorization remaining.
• ·Total SG&A expenses reached 114.5% of net sales in FY2025 vs 80.3% in FY2024.

03-03-2026

Evolution Global Acquisition Corp, a SPAC, reported total assets of $242.5M as of December 31, 2025, primarily driven by $241.2M in the trust account from its IPO, with 24M Class A shares subject to redemption at $10 per share. However, the company recorded a net loss of $4.1M for the period from inception (June 26, 2025) through December 31, 2025, including $5.0M in compensation expense, resulting in an accumulated deficit of $8.5M and shareholders' deficit of $8.5M. Cash outside the trust was $1.1M, with total liabilities of $9.8M including a $9.6M deferred underwriting fee.

• ·Period covered: Inception June 26, 2025, through December 31, 2025
• ·Basic and diluted net loss per share: $0.30 for both Class A and Class B shares
• ·Formation, general and administrative expenses: $287,063
• ·Due from Sponsor: $803

03-03-2026

CNL Healthcare Properties, Inc. filed a DEFA14A on March 3, 2026, furnishing an investor presentation under Item 7.01 of Form 8-K, providing a company update and views on the seniors housing market amid a proposed transaction with Sonida Senior Living, Inc. The presentation highlights ongoing proxy solicitations via a joint proxy statement/prospectus, with a related S-4 registration statement declared effective on January 6, 2026. No specific financial metrics, growth, declines, or period comparisons were disclosed, emphasizing risks such as illiquidity, leverage, and sector-specific challenges.

• ·Registration statement on Form S-4 (File No. 333-292187) declared effective by SEC on January 6, 2026.
• ·Company's Annual Report on Form 10-K for fiscal year ended December 31, 2024, filed March 12, 2025.
• ·Sonida's proxy statement for 2025 Annual Meeting filed April 29, 2025.

03-03-2026

Coronado Global Resources Inc., a coal producer operating in Australia and United States segments with metallurgical and thermal coal products, filed its 10-K Annual Report for the fiscal year ended December 31, 2025, on March 3, 2026. As of December 31, 2025, the company had 167,645,373 shares of common stock outstanding (including underlying CHESS Depositary Interests), with the market value of non-affiliate holdings at $73.7M as of June 30, 2025. No specific financial performance metrics such as revenue or earnings were detailed in the provided filing excerpt.

• ·Common stock par value: $0.01 per share
• ·Principal executive offices: Level 33, Central Plaza One, 345 Queen Street, Brisbane, Queensland, Australia 4000
• ·Segments: Australia Segment, United States Segment (including Buchanan and Logan, MonValley and Russell County)
• ·Publicly traded on Australian Securities Exchange as CDIs (10-for-1 convertible to common stock)

03-03-2026

Helios Technologies, Inc. reported FY2026 net sales of $839M, up 4.1% YoY from $805.9M, driven by 11.0% growth in one segment to $298.2M, while the other segment grew just 0.7% to $540.8M (flat). Gross profit rose 7.5% to $271.2M with consistent 32.3% margins across segments; however, operating income fell 19.3% to $66M due to a $25.9M goodwill impairment and a 67.2% plunge in the weaker segment's operating income to $9.7M from $29.6M. Net income increased 24.1% to $48.4M and diluted EPS to $1.45, supported by lower interest expense.

• ·Cash and cash equivalents increased to $73M from $44.1M; revolving debt down to $105.5M from $147.3M.
• ·Net cash from operating activities up to $127.3M from $122.1M; total liabilities decreased to $583M from $641M.
• ·Dividends declared per share remained flat at $0.36.
• ·Goodwill stable at $498.1M; inventories slightly down to $188.6M from $190.1M.

03-03-2026

Sturm Ruger & Co Inc (RGR) filed a DEFA14A on March 3, 2026, providing notice of its intent to file a proxy statement on Schedule 14A for the 2026 Annual Meeting of Stockholders and urging shareholders to review it and related SEC filings when available. The filing discloses that Ruger directors, executives, and employees may be participants in the proxy solicitation. Information on participants is referenced in the 10-K filed March 2, 2026 (for year ended December 31, 2025), the 2025 proxy statement filed April 17, 2025, and 8-Ks filed June 2, June 20, and September 19, 2025.

• ·10-K filed March 2, 2026 for fiscal year ended December 31, 2025.
• ·2025 proxy statement filed April 17, 2025.
• ·8-K filings on June 2, 2025; June 20, 2025; September 19, 2025.

03-03-2026

C&F Financial Corp reported consolidated net income of $27M for 2025, up 35% YoY from $20M in 2024, driven by strong growth in Community Banking (+34% to $27M) and Mortgage Banking (+108% to $2.3M with 28.9% higher loan originations). However, Consumer Finance net income declined 13% YoY to $1.2M, while Other segment losses widened to $3.8M, and ROE of 11.11% remained below 2023's 11.68%. Total assets grew to $2.67B, with net interest income up 10% to $107M and NIM expanding to 4.21%.

• ·Provision for credit losses in Community Banking was a benefit of $50K in 2025 vs provision of $1.65M in 2024.
• ·Noninterest income grew 13% YoY to $35M in 2025.
• ·Noninterest expense increased 7% YoY to $96M in 2025.
• ·Community Banking loans average balance $1.52B in 2025, up from $1.38B in 2024.
• ·Consumer Finance loans average balance $464M in 2025, down slightly from $477M in 2024.

03-03-2026

Strata Critical Medical reported FY2025 total revenue of $197.1M, up 34.3% YoY from $146.8M, with Logistics up 20.4% to $176.8M and new Clinical segment adding $20.3M; gross profit rose 39.0% to $41.1M with margins steady at 21%. However, loss from continuing operations widened to $20.1M from $16.2M as operating expenses increased 19.7% to $60.9M driven by professional fees (+132.4%) and depreciation (+469.8%), while other non-operating income fell 64.1% to $2.3M. Overall net income flipped to $41.3M profit from $27.3M loss, propelled by $61.4M gain from discontinued operations, and Adjusted EBITDA surged 274% to $14.1M.

• ·Gross margin Logistics steady at 21% (FY2025) from 20% (FY2024)
• ·Clinical gross margin 22% in debut FY2025
• ·Stock-based compensation declined 8.2% to $17.0M
• ·Basic and diluted EPS total $0.50 (FY2025) vs $(0.35) (FY2024)
• ·Amortization of intangible assets up 107.0% to $2.6M

03-03-2026

York Water Company (YORW) reported FY2025 revenue growth of 3.4% YoY to $77.5M, with net utility plant expanding 7.0% to $568.4M and total assets rising 7.5% to $680.9M amid $48.7M in utility plant additions. However, operating income declined 1.2% YoY to $27.7M, net income fell 1.3% to $20.1M, and diluted EPS decreased to $1.39 from $1.42, reflecting higher depreciation, interest expenses, and lower allowance for funds used during construction. Cash from operations was slightly down 2.3% to $29.9M, while dividends per share increased to $0.8856.

• ·Long-term debt increased to $221.9M from $205.6M.
• ·Short-term borrowings of $10.0M introduced in 2025.
• ·Proceeds from long-term debt issues: $56.8M in 2025 vs $86.7M in 2024.
• ·Deferred regulatory assets rose to $59.3M from $54.1M.

03-03-2026

CBL & Associates Properties Inc reported net income of $134.5M for FY 2025, a 136% YoY increase from $57.1M in 2024, boosted by $74.2M gains on real estate sales and other one-time items. Total revenues rose 12% YoY to $578.4M, driven by 13% higher rental revenues ($559.0M) with strong mall performance (+$71.5M), however outlet centers declined slightly (-$0.3M), open-air centers fell $6.0M, management fees dropped $2.5M, and same-center NOI was essentially flat at +0.5% ($420.5M). The company's pro-rata share of total debt was $2.5B-$2.6B as of Dec 31, 2025.

• ·Top 25 tenants account for 34.15% of total revenues from 11.5M sq ft across 1,253 stores.
• ·Ashland Town Center (Ashland, KY) opened in 2025 with 89% in-line GLA leased.
• ·Low occupancy properties include Eastland Mall (Bloomington, IL) at 48% and Meridian Mall (Lansing, MI) at 77%.
• ·Total unconsolidated debt $726.2M with $678.4M balloon payments due.
• ·Excluded property Southpark Mall debt $48.3M matures Jun-2026.

03-03-2026

Energys Group Ltd filed a Form F-1 registration statement to allow selling shareholders to resell up to 15.7M ordinary shares and 31.3M shares underlying Series A and B warrants, potentially increasing outstanding shares to 62.6M upon full warrant exercise. While the company may receive up to $23.4M in gross proceeds from cash warrant exercises for working capital, it faces significant Nasdaq delisting risk due to MVLS below $35M for 30 days ending Dec 29, 2025, with a compliance deadline of June 29, 2026. Future share sales and dilution risks could pressure the stock price, amid needs for additional financing.

• ·Nasdaq non-compliance notification received Dec 30, 2025, for MVLS below requirement over Nov 7 to Dec 29, 2025 period; 180-day compliance period ends June 29, 2026.
• ·Company incorporated in Cayman Islands, complying with Nasdaq governance post-offering instead of home country practices.
• ·No proceeds to company from resale of shares by selling shareholders; never paid cash dividends and none anticipated.

03-03-2026

Ingram Micro Holding Corp reported FY2025 net sales of $52.6B, up 9.5% YoY from $48.0B, with Asia-Pacific growing 15.3% and North America 9.1%, while EMEA rose 6.6% and Latin America a modest 3.1%. However, gross profit margin declined to 6.67% from 7.18%, operating margin slipped to 1.67% from 1.70% with North America dropping from 1.85% to 1.30%, though total operating income increased 7.2% to $877M and net income rose 24.1% to $328M. Cash from operating activities surged to $916M from $334M, while total debt decreased to $3.2B from $3.4B.

• ·Total assets increased to $21.2B from $18.8B as of Dec 28, 2024.
• ·Stockholders’ equity rose to $4.2B from $3.7B.
• ·Diluted EPS increased to $1.39 from $1.18.
• ·Comprehensive income was $574M in FY2025 vs loss of $14M in FY2024.
• ·Restructuring costs declined to $15M from $38M.

03-03-2026

Viking Holdings Ltd's FY2025 annual report shows total revenue of $6.5B, up 22% YoY from $5.3B in 2024, driven by 22% growth in cruise and land revenue to $6.1B and 24% in onboard and other to $0.45B. Operating income surged 40% to $1.5B, with net income attributable to the company at $1.1B versus $153M in 2024, and Adjusted EBITDA rose 39% to $1.9B. Adjusted EPS improved to $2.61 from $1.86, while Adjusted FCF increased 26% to $2.2B.

• ·Interest expense decreased to $363M in FY2025 from $380M in FY2024.
• ·No Private Placement derivative loss in FY2025 compared to $364M loss in FY2024.
• ·Total cruise operating expenses rose 18% YoY to $3.7B in FY2025.
• ·Selling and administration expenses increased 17% to $1.0B in FY2025.

03-03-2026

SouthState Corporation filed definitive additional proxy materials (DEFA14A) on March 3, 2026, for its 2026 Annual Meeting of Shareholders to be held virtually on April 15, 2026, at 9:30 AM EDT. Shareholders will vote on the election of 14 director nominees (all recommended FOR by the Board), an advisory 'say on pay' resolution for executive compensation (FOR), and ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026 (FOR). Voting must occur by April 14, 2026 (11:59 PM ET for direct shares) or April 12, 2026 (for plan-held shares), with proxy materials available online or requestable by April 1, 2026.

• ·Meeting address/reference: 1101 First Street South, Winter Haven, FL 33880
• ·Virtual meeting URL: www.virtualshareholdermeeting.com/SSB2026
• ·Proxy materials request methods: www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com (include control number)

03-03-2026

Select Medical Holdings Corporation (SEM) entered into a Merger Agreement on March 2, 2026, with Stallion Intermediate Corporation and its subsidiary Merger Sub, under which SEM shareholders will receive $16.50 per share in cash, subject to stockholder approvals (majority overall and majority excluding Parent affiliates and Rollover Holders), regulatory clearances including HSR antitrust review and healthcare approvals, and no Company Material Adverse Effect. The transaction was unanimously approved by a Special Committee of independent directors and the full Board (disinterested members), with committed equity from WCAS XIV, L.P. and debt financing; post-merger, SEM shares will delist from NYSE. Termination rights include an Outside Date of December 1, 2026 (extendable to March 1, 2027), with fees of $66.5M payable by SEM under certain conditions and $133M by Parent if it fails to close after conditions are met.

• ·Merger closing subject to customary conditions including no governmental injunctions and Parent's representations/warranties being true (with materiality qualifiers).
• ·Company Restricted Shares vest fully immediately prior to Effective Time (except Rollover Shares).
• ·Parent has no financing condition; obligations backed by Equity Commitment Letter from WCAS XIV, L.P. and Debt Commitment Letter.
• ·Limited Guaranty by WCAS XIV, L.P. for certain Parent obligations including Parent Termination Fee.

03-03-2026

Carrier Global Corporation (CARR) filed Definitive Additional Materials (DEFA14A) supplementing its 2026 Proxy Statement on March 03, 2026. The filing contains standard SEC Schedule 14A headers with no fee required and is marked as Definitive Additional Materials. No financial results, operational updates, or voting items are detailed in the provided content.

• ·Filing Type: DEFA14A (Definitive Additional Materials)
• ·No filing fee required

03-03-2026

Ameresco's 2025 revenues grew 9.2% YoY to $1.93B, propelled by Europe segment surging 111.1% to $529M, but offset by U.S. Federal declining 21.4% to $293M, North America Regions flat at 0.7% growth to $885M, Renewable Fuels down 8.6%, and All Other dropping 29.0%. Gross profit increased 18.7% to $304M with operating income up 13.3% to $123M; however, net income attributable to common shareholders decreased 22.0% to $44M, and operating cash flow swung to negative $80M from positive $118M. Working capital improved to $524M, though cash and equivalents fell to $72M.

• ·Availability under revolving credit facility improved to $45M from $21M as of Dec 31, 2025.
• ·Gain on sale of business was $0 in 2025 vs $38M in 2024.
• ·Asset impairments decreased 69.7% to $3.7M in 2025.
• ·Interest expense, net, rose 25.3% to $88M in 2025.

03-03-2026

Billion Group Holdings Limited, a Cayman Islands exempted company with operations conducted through its wholly-owned Hong Kong subsidiary Billion Enterprise International Limited in the food and kindred products manufacturing sector, has filed a Form F-1 registration statement for an initial public offering of 3,750,000 Ordinary Shares priced between $4.00 and $5.00 per share, with plans to list on the Nasdaq Capital Market under the symbol BGHL. Post-offering, the controlling shareholder will own 56.5% of the Ordinary Shares. The prospectus emphasizes high investment risks, including potential PRC oversight over Hong Kong operations, restrictions on fund transfers, and the possibility of material adverse impacts on business or share value.

• ·Company incorporated in Cayman Islands with principal executive offices in Sheung Wan, Hong Kong.
• ·Standard Industrial Classification: Food & Kindred Products [2000].
• ·Emerging growth company status with reduced reporting requirements.
• ·No variable interest entity (VIE) structure; 100% equity ownership in Hong Kong operating subsidiary.
• ·All operations, clients, and advertising market in Hong Kong; no mainland China presence or suppliers.

03-03-2026

HNI Corporation's FY2025 net sales rose 12.4% YoY to $2,839M from $2,526M, with Workplace Furnishings up 14.6% to $2,164M and Residential Building Products up 5.7% to $675M. However, operating income fell 39.0% to $126M due to $94.6M acquisition costs, higher selling/admin expenses (up 14.2%), and restructuring charges, leading to net income of $54.2M, down 61.1% YoY, and diluted EPS of $1.11 versus $2.88. While Residential segment margins improved 60 bps to 18.0%, Workplace margins contracted 50 bps to 8.5%, and effective tax rate spiked to 40.2% from 22.2%.

• ·Diluted EPS $1.11 in FY2025 vs $2.88 in FY2024.
• ·Gross margin expanded 50 bps to 41.4% of sales.
• ·FY2023 net sales were $2,434M for comparison.
• ·Credit Agreement dated September 5, 2025 with Wells Fargo.
• ·Filing date: March 03, 2026; FY2025 ended January 3, 2026.

03-03-2026

Prime Medicine, Inc. reported FY2025 total revenue of $4.6M, up 55% YoY from $3.0M, primarily from collaboration revenue with related parties. However, operating expenses rose 4% YoY to $213M, driving net loss higher to $201M from $196M, while cash used in operations increased 32% to $163M and cash equivalents declined sharply to $63M from $182M. Total assets grew to $343M from $298M, supported by $138M raised in a public offering, but stockholders' equity fell to $121M from $153M.

• ·R&D expenses increased to $160.6M from $155.3M YoY.
• ·Financing activities provided $151.5M in FY2025, down from $195.9M in FY2024.
• ·Property and equipment, net declined to $20.6M from $24.4M.
• ·Research and development funding liability rose to $18M from $6M.

03-03-2026

Janus Henderson Group plc filed a DEFA14A on March 3, 2026, providing additional information in connection with a proposed transaction, following a preliminary proxy statement and Schedule 13E-3 filed on February 27, 2026. The filing urges shareholders to review these documents and prior annual meeting proxy materials for details on directors, executives, and potential solicitation participants. No financial metrics or performance data are disclosed in this communication.

• ·Annual Meeting Proxy Statement filed with SEC on March 21, 2025.
• ·References year ended December 31, 2025.
• ·SEC filings available at https://www.sec.gov or https://ir.janushenderson.com.

03-03-2026

TNL Mediagene filed an F-1 registration statement on March 3, 2026, to register the resale of up to 1,600,354 ordinary shares (including up to 1,250,000 from the Second Note to 3i, LP, 300,354 2025 PIPE Shares, and 50,000 2025 Vendor Shares) and 145,844 3i Warrants plus underlying shares by selling securityholders. This follows the issuance of the Second Note on December 8, 2025, with $1.67M principal ($1.5M proceeds after 10% OID), after full repayment of the prior Initial Note on November 11, 2025, via $1.54M cash and 500,111 shares, and a 1-for-20 reverse share split on December 22, 2025. No operational or financial performance metrics are disclosed in the filing.

• ·3i Warrants have 5-year term, cash exercise if registration effective, otherwise cashless.
• ·Second Note maturity: 18 months from Dec 8, 2025; no installments first 6 months; optional prepayment with make-whole.
• ·3i limited to higher of 10% daily trading volume or $50,000 in daily sales of converted shares.
• ·Prior F-1 registrations (333-284411, 333-287669) effective May 23, 2025 and Aug 22, 2025 for Initial Note shares.

03-03-2026

Bloomin' Brands, Inc. filed definitive additional proxy materials (DEFA14A) on March 3, 2026, consisting primarily of SEC headers, a notice and access page, and graphical content related to proxy solicitation under Section 14(a) of the Securities Exchange Act of 1934. No financial results, period-over-period comparisons, or operational metrics are present in the readable content. The filing appears to support shareholder communications for an upcoming meeting, with no discernible positive or negative performance indicators.

• ·Company address: 2202 North West Shore Boulevard, Suite 500, Tampa, FL 33607
• ·Business phone: 813-282-1225
• ·Fiscal year end: December 27
• ·State of incorporation: Delaware
• ·Central Index Key: 0001546417
• ·SEC file number: 001-35625

03-03-2026

OFS Capital Corp's FY 2025 10-K shows NAV per share declining sharply to $9.19 from $12.85 in FY 2024 (-28.5% YoY), with NAV total dropping to $123.2M from $172.2M and total return on NAV at -16.7% versus +23.7% prior year. Net investment income fell 26.0% YoY to $12.4M from $16.7M amid lower interest income ($38.4M vs $43.3M) and dividend income ($1.9M vs $4.1M), while net losses on investments widened to $45.0M from gains of $11.7M. Portfolio fair value decreased to $280.4M from $332.8M, with first lien debt at $170.4M (down from $189.9M), though number of portfolio companies remained flat at 43.

• ·Unsecured Notes Due February 2026 ($125.0M) fully redeemed on February 9, 2026; BNP Facility fully repaid and terminated on February 18, 2026.
• ·High sales price discount to NAV reached -15.0% in Q4 FY 2025; market value end of period $4.76 per share.
• ·Total annual expenses estimated at 22.56% of net assets, including 12.16% interest on borrowed funds.
• ·Portfolio turnover declined to 13.2% in FY 2025 from 23.1% in FY 2024.

03-03-2026

For the year ended December 31, 2025, Scholar Rock Holding Corp reported total operating expenses of $384.6M, up 52.6% YoY from $252.1M in 2024, driven by a 161.0% surge in general and administrative expenses to $176.2M while research and development expenses rose a more modest 12.9% to $208.4M; this resulted in a net loss widening 53.5% to $377.9M. Total liquidity decreased to $367.6M from $437.3M, with cash equivalents increasing to $323.5M but offset by a sharp decline in marketable securities to $44.0M. Other income grew 16.4% to $6.7M.

• ·Unfavorable pricing and reimbursement decisions in the EU could significantly delay or limit patient access to apitegromab, if approved, and materially reduce anticipated revenues due to lengthy negotiations and potential price reductions.
• ·Cash and cash equivalents increased to $323.5M as of Dec 31, 2025 from $177.9M as of Dec 31, 2024, while marketable securities declined to $44.0M from $259.4M.

03-03-2026

Passage Bio, Inc. (PASG) reported a reduced net loss of $45.5M for the year ended December 31, 2025, compared to $64.8M in 2024, driven by lower research and development expenses ($23.3M, down 42% YoY) and general and administrative expenses ($19.9M, down 21% YoY). However, impairment of long-lived assets increased 17% to $6.1M, other income declined 33%, and the company continues to incur significant operating losses as a clinical-stage genetic medicines firm with no profitability in sight. The firm is advancing PBFT02 in expanded trials for FTD-GRN, FTD-C9orf72, ALS, and AD via the upliFT-D trial.

• ·Decrease of $2.6M in facility and other expenses primarily due to decreased depreciation from disposal of laboratory equipment.
• ·Clinical expansion of PBFT02 to FTD-C9orf72 cohorts in upliFT-D trial, plus exploration in ALS and AD.

03-03-2026

West Bancorporation, Inc. issued a DEFA14A notice for its 2026 Annual Meeting on April 23, 2026, at 4:00 p.m. Central Time, where shareholders will vote on electing eight director nominees, non-binding approval of 2025 named executive officer compensation, and ratification of RSM US LLP as independent auditors for 2026. The board recommends 'For' all proposals, with voting deadlines of April 22, 2026 (11:59 p.m. ET) for regular shares and April 20, 2026 (11:59 p.m. ET) for plan shares.

• ·Meeting location: 3330 Westown Parkway, West Des Moines, IA 50266
• ·Proxy materials request deadline: April 9, 2026
• ·Control numbers referenced: V82971-P41830, V82972-P41830

03-03-2026

Amylyx Pharmaceuticals reported zero product revenue in 2025 versus $87.4M in 2024 (-100% YoY), contributing to a narrowed net loss of $144.7M (-52% YoY improvement from $301.7M) due to sharp cuts in operating expenses (-62% to $153.3M), including R&D (-13%) and SG&A (-45%). Cash and equivalents strengthened to $226.7M from $77.4M, supported by $257M in financing activities, while total assets grew to $332.6M. However, the company remains unprofitable with accumulated deficit expanding to $751.4M and no revenue generation.

• ·Marketable securities decreased to $90.3M from $99.1M as of Dec 31, 2025.
• ·Stock-based compensation expense declined to $27.6M from $33.0M YoY.
• ·Weighted-average shares used in net loss per share increased to 94.6M from 68.1M.
• ·Net cash provided by investing activities dropped to $14.0M from $75.7M.

03-03-2026

Medline Inc. filed an S-1 registration statement on March 3, 2026, for a secondary public offering of Class A common stock by selling stockholders, assuming no exercise of the underwriters' option for up to 11.25 million additional shares. The company positions itself as the largest med-surg products and supply chain solutions provider, offering approximately 335,000 products across Medline Brand (~190,000 items from 30 facilities and 600+ partners) and Supply Chain Solutions (~145,000 third-party items) segments, supported by 70 distribution facilities (29 million sq ft), 2,100 trucks, and 95% next-day U.S. delivery, with net sales CAGR of 18% since 1966. No period-over-period financial comparisons or negative metrics are provided in the excerpt.

• ·Founded in 1966.
• ·Sponsor Acquisition on October 21, 2021, by Blackstone, Carlyle, and H&F.
• ·Prior IPO closed on December 18, 2025.
• ·Principal Stockholders: Blackstone, Carlyle, H&F, and Mills Family.

03-03-2026

03-03-2026

On Holding AG reported FY2025 net sales of CHF 3,014.0M, up 30.0% YoY (35.6% constant currency) from CHF 2,318.3M, fueled by DTC growth of 33.7%, Asia-Pacific sales surging 96.4%, apparel up 68.2%, and accessories up 124.1%. However, net income fell 15.9% to CHF 203.7M from CHF 242.3M, with net income margin contracting to 6.8% from 10.4% due to a sharply negative net financial result of CHF (171.8)M versus CHF 68.1M prior year and SG&A expenses rising 27.0%; operating result rose 78.2% to CHF 377.0M. In Q4 2025, net sales grew to CHF 743.8M from CHF 606.6M, but net income declined to CHF 69.1M from CHF 89.5M.

• ·Gross profit margin expanded to 62.8% from 60.6% YoY.
• ·Adjusted EBITDA increased to CHF 567.0M (18.8% margin) from CHF 387.6M (16.7% margin).
• ·Basic EPS Class A declined to CHF 0.62 from CHF 0.75.
• ·Americas represented 57.7% of net sales, down from 63.9%.
• ·Income tax expense decreased 95.9% to CHF (1.5)M.

03-03-2026

Magnitude International Ltd reported revenue growth of 11% YoY to S$24.2M in FY2024 from S$21.9M in FY2023, with gross profit rising 45% to S$3.8M; however, revenue declined sharply 37% YoY to S$15.4M in FY2025, gross profit fell 38% to S$2.4M, and net profit plummeted 98% to S$43K amid heavy reliance on top customers (76.7% of FY2025 revenue). Operating cash flow turned negative at S$(0.9M) in FY2025 after positives in prior years, while total liabilities rose to S$7.6M. Customer concentration eased slightly to 76.7% from top five but remains a key risk.

• ·Over 80% of workforce comprised foreign employees in FY2024 and FY2025.
• ·Defect liability period generally 12 to 18 months.
• ·Trade and other payables increased to S$5.2M carrying value as of April 30, 2025.
• ·Secured term loan carrying value S$1.8M as of April 30, 2025.
• ·Net cash used in investing activities increased to S$0.45M in FY2025.

03-03-2026

Subversive Bitcoin Acquisition Corp., a Cayman Islands blank check company (SPAC), filed Amendment No. 3 to its Form S-1 for a $100M IPO of 10M units at $10 each, each unit consisting of one Class A ordinary share and one-half redeemable warrant (exercisable at $11.50 post-business combination). Proceeds will be allocated $90M ($103.5M if over-allotment exercised) to a cash trust and $10M ($11.5M if over-allotment) to a bitcoin trust account, with unique bitcoin treasury strategy differing from standard SPACs and carrying associated risks. Sponsor Subversive Bitcoin Sponsor LLC committed to 350K placement units for $3.5M and holds 2.875M Class B founder shares purchased for $25K.

• ·IPO closing targeted as soon as practicable after SEC effectiveness.
• ·24-month deadline to complete initial business combination (extendable by shareholder vote).
• ·Warrants exercisable 30 days post-business combination, expire 5 years after or earlier on redemption/liquidation.
• ·Founder shares maintain ~20% ownership post-IPO, with anti-dilution adjustments.

03-03-2026

DMINT, Inc., a finance services company in crypto assets and subsidiary of OLB, filed an S-1/A registration statement on March 3, 2026, for its initial public offering (Registration Number 333-292762). Upon IPO consummation, interim executives Ronny Yakov (CEO) and Patrick Smith (CFO) will receive $1 per year each, while Thomas Fontanilla receives $135,000 annually; no employment agreements exist, no equity awards were outstanding as of December 31, 2025, and no employee benefits are provided. The company will adopt a Clawback Policy compliant with Exchange Act Section 10D and the 2026 Equity Incentive Plan, with share reserves starting at [●] and annual increases up to 2% of outstanding shares through 2036.

• ·No outstanding equity awards as of December 31, 2025.
• ·No employment agreements currently in place.
• ·Directors receive no fixed compensation, only reimbursement for reasonable out-of-pocket expenses.
• ·No retirement, health, or welfare benefits provided to employees.
• ·2026 Plan share reserve: initial [●] shares, plus annual increases through January 1, 2036, equal to the lesser of 2% of outstanding shares or Board-determined amount.

03-03-2026

Hycroft Mining Holding Corp reported a narrowed net loss of $40.7M for the year ended December 31, 2025, compared to $60.9M in 2024, with improvements in exploration costs (-24% YoY), interest expense (-45% YoY), and a turnaround in stockholders' equity to positive $213.7M from a $33.4M deficit. However, net cash used in operating activities worsened significantly to $82.9M from $35.9M, loss from operations edged up 1.5% YoY to $44.5M, and mine site costs more than doubled to $14.7M. Cash and equivalents surged 267% to $181.7M, driving total assets up 88% to $263M.

• ·Remediation and reclamation expenditures total $117.0M, with $110.4M due more than 5 years out.
• ·Debt, net reduced to $0 from $125.0M as of Dec 31, 2025.
• ·Net cash provided by financing activities: $205.9M in 2025 vs $(25.9M) in 2024.
• ·Loss per share improved to $(0.94) from $(2.63).

03-03-2026

Encore Medical, Inc., a structural heart device company developing transcatheter septal occlusion devices for PFO and ASD defects, filed Amendment No. 2 to its S-1 registration statement on March 3, 2026, for an initial public offering of 3,000,000 shares of common stock at $5.00 per share, targeting gross proceeds of $15M ($13.8M net before expenses). The company, founded in 2017 with over 35,000 prior successful implants and CE Mark approval, markets products outside the US and eyes a $1.5B annual US PFO stroke prevention market opportunity based on 139,000 patients at $11,000 average price. Listing on NYSE American under 'EMI' is contingent on approval, with underwriters granted a 45-day option for 450,000 additional shares.

• ·Company incorporated in Minnesota, SIC code 3841, EIN 82-2906303, headquartered at 2975 Lone Oak Drive, Suite 140, Eagan, MN 55121.
• ·Emerging growth company and smaller reporting company, non-accelerated filer.
• ·CE Mark approval for products sold via distribution partners outside the US.
• ·Fiscal years end December 31; references to FY 2024 and 2025.

03-03-2026

Anika Therapeutics reported revenue of $112.8M for the year ended December 31, 2025, down 6% YoY from $119.9M in 2024, with gross profit declining 16% to $63.8M and gross margin compressing to 57% from 63% due to a 12% rise in cost of revenue. While total operating expenses fell 8% to $74.9M, driven by a 12% drop in SG&A, the operating loss widened 117% to $11.1M. Net loss improved 81% to $10.9M from $56.4M, primarily due to a sharp 98% reduction in losses from discontinued operations.

• ·Loss from continuing operations worsened 13% YoY to $10.0M in 2025.
• ·Provision for income taxes decreased 89% to $0.7M.
• ·Loss from discontinued operations improved 98% to $0.9M.

03-03-2026

Digital Asset Acquisition Corp. (DAAQU), a SPAC, reported total assets of $178.3M as of December 31, 2025, up significantly from $25K at inception-end 2024, driven by $177.1M in marketable securities held in the Trust Account from its IPO of 17.25M Class A ordinary shares at $10.27 redemption value. For the year ended December 31, 2025, the company achieved net income of $4.2M primarily from $4.6M interest on Trust Account securities, however, it posted an operating loss of $0.4M from G&A expenses and shareholders' equity shifted to a $5.8M deficit from a $20K surplus due to accretion on redeemable shares.

• ·Company inception date: December 9, 2024
• ·Underwriters’ over-allotment option exercised in full on April 30, 2025, releasing 750,000 Class B ordinary shares from forfeiture
• ·Redemption value of Class A ordinary shares: $10.27 per share as of Dec 31, 2025
• ·Basic and diluted net income per share: $0.25 for both Class A and Class B ordinary shares for year ended Dec 31, 2025

03-03-2026

Real Asset Acquisition Corp., a SPAC, reported total assets of $178.3M as of December 31, 2025, up dramatically from $25K at December 31, 2024 (inception stub period), driven by $177.1M in marketable securities held in Trust Account from IPO of 17.25M Class A ordinary shares at $10.27 redemption value. For the year ended December 31, 2025, the company posted net income of $4.25M, boosted by $4.61M in Trust Account earnings offsetting a $0.37M operating loss; however, shareholders' equity swung to a $5.83M deficit from a $24K surplus due to $15.86M accretion on redeemable shares, and operating losses increased significantly from the prior stub period.

• ·Inception date: December 9, 2024.
• ·Underwriters’ over-allotment option exercised in full on April 30, 2025, releasing 750,000 Class B shares from forfeiture.
• ·Class A ordinary shares redemption value: $10.27 per share as of Dec 31, 2025.
• ·Basic and diluted EPS for Class A and Class B: $0.25 for year ended Dec 31, 2025.

03-03-2026

Breeze Acquisition Corp. II, a blank check company, filed Amendment No. 2 to its S-1 registration statement on March 3, 2026, for an IPO of 12,947,500 units (assuming no over-allotment exercise), comprising ordinary shares and Share Rights. The sponsor, Breeze Sponsor II, LLC, acquired 5,050,676 founder shares for $25,000 and committed to purchasing 447,500 private placement units for $4.475M at $10.00 per unit. Post-offering, ordinary shares would total 17,639,392 and Share Rights 2,589,500, with founder shares subject to lock-up restrictions until six months after a business combination or other triggers.

• ·Founder shares issued: 4,791,667 on September 8, 2025, and 259,009 on October 21, 2025.
• ·Up to 658,784 founder shares to be surrendered if over-allotment exercised.
• ·Each Share Right converts to one-fifth of one ordinary share upon initial business combination (must hold in multiples of five).
• ·Founder shares represent 26% of outstanding shares post-offering (excluding private and representative shares).
• ·Private placement units and constituent securities subject to 30-day post-business combination transfer restriction.
• ·Lock-up on founder shares: until 6 months after business combination or price trigger of $15.00/share for 20/30 trading days.

03-03-2026

Heartland Express reported operating revenue of $806M for the year ended December 31, 2025, down 23.1% YoY from $1.05B in 2024, with operating revenue excluding fuel surcharge declining 22.4% to $709M from $914M. Operating loss widened to $57.4M from $20.2M, driving the operating ratio to 107.1% from 101.9%, while net loss margin deteriorated to 6.5% from 2.8%; however, rent and purchased transportation improved to 6.4% of revenue from 7.6%, and gain on disposal of property strengthened to 2.9% from 0.7%. Adjusted operating ratio was 104.7% versus 101.7% prior year.

• ·Salaries, wages, and benefits flat at 40.8% of revenue YoY.
• ·Insurance and claims rose to 7.2% of revenue from 4.9% YoY.
• ·Depreciation and amortization increased to 19.7% of revenue from 17.3% YoY.
• ·Operations and maintenance up to 7.8% from 6.8% YoY.

03-03-2026

NB Bancorp reported GAAP net income of $50.3M for 2025, up 19% YoY from $42.1M in 2024, driven by higher pre-tax income of $71.1M (up 21% YoY) and operating net income of $66.2M (up 46% YoY). However, noninterest expenses rose 34% YoY to $137.9M due to $17.3M in merger-related costs from Provident Bancorp integration, and non-accrual loans surged 213% to $43.4M, lifting the non-performing assets ratio to 0.62% from 0.27%. Operating efficiency improved slightly to 56.2% from 58.4%, with average assets growing 14% to $5.46B.

• ·GAAP diluted EPS $1.34 in 2025 (up 25% YoY from $1.07); operating diluted EPS $1.76 (up 53% YoY from $1.15).
• ·Noninterest income GAAP $16.2M in 2025 (up 29% YoY from $12.6M).
• ·One-to-four-family residential non-accrual loans declined 7% YoY to $2.7M; consumer non-accrual loans down 8% YoY to $2.2M.
• ·Operating ROAE improved to 8.73% from 6.09% YoY.

04-03-2026

Black Rock Coffee Bar, Inc. (BRCB) grew total stores to 181 from 149 with 32 net new openings, boosting total revenue 24.5% YoY to $200.3M and same-store sales growth to 10.1% from 6.3%, while average unit volume rose to $1.286M from $1.186M. However, income from operations plummeted 85.1% to $0.9M from $6.0M, and net loss widened 130.1% to $16.5M from $7.2M, driven by SG&A expenses surging 63.6% to $41.3M amid rising store operating costs.

• ·Store operating costs and expenses rose 22.2% YoY to $141.6M, with other store operating expenses up 28.4%.
• ·Pre-opening costs increased 28.2% to $4.3M.
• ·Interest expense, net improved 15.9% to $9.4M due to lower expense.
• ·Filing date: March 04, 2026 for year ended December 31, 2025.

04-03-2026

National Vision Holdings, Inc. reported FY2025 total net revenue of $1.99B, up 9.0% YoY from $1.82B, with comparable store sales growth accelerating to 5.9% from 1.9% driven by America's Best (+6.3%) and other owned segments. The company achieved net income from continuing operations of $29.6M, reversing a $27.2M loss, alongside Adjusted Operating Income of $102.5M (up 56% YoY) and Adjusted EBITDA of $193.0M (up 24%). However, new store openings slowed to 33 from 69, services and plans revenue grew slower at 6.3% versus 9.7% for products, and SG&A expenses rose 8.3% to $1.02B.

• ·Asset impairment declined to $2.0M from $39.9M YoY.
• ·Corporate and other revenue fell to $21.0M (1.0% of total) from $27.6M (1.5%).
• ·Adjusted Diluted EPS from continuing operations rose to $0.80 from $0.52.
• ·Stores in Fred Meyer segment reduced from 29 to 18.

04-03-2026

Horizon Technology Finance Corporation (HRZN) announced monthly cash distributions of $0.06 per share for April, May, and June 2026, totaling $0.18 per share, payable on April 15, May 15, and June 16, 2026, respectively. Since its 2010 IPO, Horizon has distributed a total of $360M to shareholders. The board's decision factors in results of operations, spillover income, and the anticipated merger with Monroe Capital Corporation (MRCC), with no declines or flat metrics reported.

• ·Ex-Dividend/Record Dates: March 16, 2026 ($0.06); April 16, 2026 ($0.06); May 18, 2026 ($0.06)
• ·Payment Dates: April 15, 2026; May 15, 2026; June 16, 2026
• ·Related SEC Registration Statement: File No. 333-290114
• ·HRZN Proxy Statement filed April 17, 2025 (amended May 15, 2025); MRCC Proxy Statement filed April 21, 2025

04-03-2026

Dakota Gold Corp. announced that its publicly traded warrants (DC.WS), each exercisable for one share of common stock at $2.08, will expire on March 15, 2026, with trading ceasing on or about March 13, 2026, ahead of NYSE American filing a Form 25 for delisting. The company's common stock (DC) will continue trading on NYSE American. This is a routine expiration event with no reported financial impact.

• ·Warrants terms referenced from Form of Common Stock Purchase Warrant in S-1/A filed May 6, 2022
• ·Company is an emerging growth company
• ·Principal executive offices: 106 Glendale Drive, Suite A, Lead, South Dakota 57754

04-03-2026

Kontoor Brands reported FY2025 net revenues of $3.15B, up 21% YoY from $2.61B, driven by the Helly Hansen acquisition ($476M), organic growth ($61M), and favorable FX ($8M); gross margin improved to 45.2% from 44.5%. However, operating income declined to $337M (10.7% margin) from $342M (13.1% margin) due to higher SG&A at 34.5% of revenues (vs 31.4%), with Wrangler up 6% in revenue but Lee down 5.1% with profit -23.1%. Helly Hansen contributed $460M revenue with 6.9% margin in its first year.

• ·Repurchased 369,955 shares under public program at weighted avg $67.58/share, $190M remaining authorization.
• ·SG&A expenses rose to 34.5% of revenues from 31.4%.
• ·Wrangler operating margin expanded to 23.0% from 20.3%.
• ·Other revenues surged 153% to $27.8M with margin turning positive at 13.7%.

04-03-2026

Ziff Davis, Inc. and its subsidiary Ziff Davis, LLC entered into a Securities Purchase Agreement dated March 2, 2026, to sell all outstanding equity interests in specified Transferred Entities (listed on Schedule I) and related Irish assets to Accenture Inc., subject to customary closing conditions and adjustments outlined in Section 2.2. The agreement includes ancillary documents such as an Irish Asset Purchase Agreement, Transition Services Agreement, Escrow Agreement, and employment agreements for Key Employees effective upon closing. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Agreement executed on March 2, 2026; SEC 8-K filed March 4, 2026.
• ·Involves Irish Seller and Specified Irish Assets via separate Irish Asset Purchase Agreement (Exhibit A).
• ·Key Employees (listed in Purchaser Disclosure Schedule Section 1.1(a)) have executed employment agreements conditioned on closing.
• ·Closing subject to conditions in Article IX, including regulatory approvals and no material adverse changes.

04-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 4, 2026, announcing the issuance of a press release titled 'AITX's RAD Channel Partner Expands Detection to Guard Response Ecosystem,' attached as Exhibit 99.1. The filing discloses a positive development in channel partner expansion integrating detection capabilities into the Guard Response Ecosystem. No financial impacts or quantitative metrics were reported.

04-03-2026

CDT Environmental Technology Investment Holdings Ltd (CDTG) filed an F-1 registration statement on March 04, 2026, for a proposed IPO of Class A common stock. The filing includes financial statements for the six months ended June 30, 2025 (H1 FY2025) compared to H1 FY2024, and full-year FY2024 vs FY2023, focusing on sewage treatment systems and services through multiple Chinese subsidiaries. No specific financial metrics such as revenue or net income are detailed in the provided excerpt.

• ·Subsidiaries operate primarily in China across locations including Shenzhen, Beijing, Fujian, Tianjin, Chongqing, and others.
• ·Currencies referenced: CNY (Chinese Yuan), HKD (Hong Kong Dollar).
• ·Prior IPO activity noted around April 21-22, 2024.
• ·Balance sheet components include Common Stock, Additional Paid-in Capital, Retained Earnings (Statutory Reserves and Unrestricted), Accumulated Other Comprehensive Income, Noncontrolling Interest.
• ·Property categories: Buildings, Equipment (min/max depreciation), Furniture and Fixtures (min/max), Automobiles (min/max).

04-03-2026

U.S. Energy Corp. (USEG) sold an additional 6,525,843 shares of common stock to Roth Principal Investments for $7.3M pursuant to a $25M Common Stock Purchase Agreement originally entered on October 9, 2025, following a prior sale of 2M shares for $2M reported on February 10, 2026. This brings total shares outstanding to 44.3M, representing 19.1% of shares outstanding as of September 30, 2025 and causing significant dilution to existing shareholders. While the equity raise enhances liquidity, the private placement exceeds the 5% disclosure threshold under Item 3.02.

• ·Form S-1 Registration Statement for resale of shares declared effective December 1, 2025.
• ·Shares issued in reliance on Section 4(a)(2) exemption as private transaction to accredited investor.
• ·Original Purchase Agreement filed as Exhibit 10.1 to October 9, 2025 Form 8-K.

04-03-2026

Xponential Fitness reported system-wide sales growth of 13% YoY to $1.75B in 2025, with global studios increasing 7% to 3,097 and franchise revenue rising 10% to $193M, driving operating income of $20M versus a $54M loss in 2024. However, total revenue declined 2% YoY to $315M, same-store sales were flat at 0%, new studio openings dropped 20% to 341, and segments like equipment revenue (-35%) and merchandise (-12%) saw sharp declines, resulting in a net loss of $54M (improved from $99M but worse than 2023's $6M loss). AUV LTM edged up 2% to $695 but quarterly AUV declined 2% to $683.

• ·North America new studio openings net 2025: 160 (global net: 201)
• ·International franchise licenses sold new 2025: 112 (vs North America 67)
• ·Impairment of goodwill and other noncurrent assets 2025: $33M (down from $63M in 2024)
• ·Remaining studios obligated to open under MFAs EOY 2025: 767 (flat from 763 in 2024)

04-03-2026

Sky Acquisition Group filed an S-1/A registration statement on March 3, 2026, detailing its proposed IPO of 15,000,000 units, with no units outstanding prior to the offering. Post-offering, the company will have 20,000,000 ordinary shares outstanding (including conversion of 5,000,000 Class B founder shares) and 11,930,000 warrants, following the sponsor's purchase of 5,750,000 Class B founder shares on December 3, 2025, for $25,000. Warrants are exercisable at $11.50 per Class A ordinary share starting 30 days after the initial business combination, with no financial performance metrics or declines reported as this is a pre-operational SPAC.

• ·Separate trading of Class A ordinary shares and warrants prohibited until Form 8-K filed with audited balance sheet post-closing.
• ·Warrants expire 7 years after initial business combination or earlier upon redemption/liquidation.
• ·Up to 750,000 founder shares subject to forfeiture depending on underwriters’ over-allotment option exercise.
• ·Founder shares represent approximately 25% of outstanding shares post-offering on as-converted basis.

04-03-2026

On February 19, 2026, the disinterested members of the Board of Directors of Charles & Colvard, Ltd. approved reimbursement of $406,188.72 in expenses, including legal fees and solicitation costs, to Riverstyx Fund, LP—a shareholder affiliated with Board members Benjamin Franklin IV and Duc Pham—for its proxy solicitation related to the 2025 Annual Meeting of Shareholders. Interested Board members recused themselves from the decision. The reimbursement is deferred until the Company achieves a stronger financial position, reflecting considerations of governance improvements and majority shareholder support for the nominees.

• ·Approval contingent on conserving Company's cash position and deferred until stronger financial position.
• ·Board considered factors including shared benefits to Company and shareholders from Board reconstitution, majority shareholder vote for nominees, and common practice in proxy contest settlements.

04-03-2026

For FY ended October 31, 2025, MaxsMaking Inc. reported revenue growth of 36.33% YoY to $29.2M, primarily driven by Mainland China sales surging 54.13% to $26.6M. However, cost of sales rose 52.34% leading to a 34.11% decline in gross profit to $2.6M, while operating expenses increased 42.25% and income from operations fell 95.30% to $0.1M, resulting in net income plummeting 99.04% to $18K. Compared to FY2024 (which itself saw revenue decline 18.38% from FY2023), profitability deteriorated sharply despite top-line expansion.

• ·Asia (ex-Mainland China) sales declined 59.44% YoY to $0.8M (2.77% of total), Europe down 29.89% to $1.3M (4.34% of total)
• ·General and administrative expenses surged 132.97% YoY to $1.4M in FY2025
• ·Reliance on PRC subsidiaries for dividends poses cash transfer risks; unpatented technology vulnerable to imitation
• ·IPO consummated July 8, 2025

04-03-2026

FACT II Acquisition Corp. (FACT) filed a Form 425 on March 4, 2026, disclosing a LinkedIn post by Richard Nespola, Jr., sponsor team member, dated March 3, 2026, relating to the proposed business combination with Precision Aerospace & Defense Group, Inc. (PAD). The filing consists primarily of forward-looking statement disclaimers, extensive risk factors including regulatory hurdles, shareholder approvals, and potential redemptions, and directs investors to the pending Form S-4 Registration Statement for details. No financial metrics or performance data are provided.

• ·Commission File Number: 001-42421
• ·Registration Statement on Form S-4 filed with the SEC (not yet effective)

04-03-2026

Archimedes Tech SPAC Partners II Co. reported total assets of $241.3M as of December 31, 2025, primarily from $239.9M in its Trust Account following its February 12, 2025 IPO of 23M Units, with net income of $8.0M for the year driven by $8.7M in interest income. However, operating losses reached $0.8M from G&A expenses, shareholders' deficit expanded to $6.7M due to $24.6M accretion on redeemable shares, compared to a minor $54k deficit at year-end 2024 pre-IPO. The 2024 inception period showed a $79k net loss with negligible assets.

• ·IPO consummated on February 12, 2025, with full exercise of 3M over-allotment option; 750k sponsor shares no longer subject to forfeiture.
• ·Company inception date: June 7, 2024.
• ·Ordinary shares subject to redemption valued at $10.43 per share as of Dec 31, 2025.
• ·Promissory note to related party of $192k repaid by Dec 31, 2025.

04-03-2026

PetVivo Holdings, Inc. filed a Form 8-K on March 4, 2026, reporting an event dated March 3, 2026, to disclose an Investor Presentation (Exhibit 99.1) dated March 2026 under Item 7.01 Regulation FD for use in investor conferences and other forums. The presentation is furnished pursuant to Regulation FD and not deemed filed with the SEC. The filing was signed by CEO John Lai; no specific financial metrics or performance data are detailed in the filing itself.

• ·Registrant is an emerging growth company.
• ·Securities: Common Stock (PETV) on OTCQX; Warrants (PETVW) on OTCID.
• ·Principal executive offices: 5151 Edina Industrial Blvd. Suite 575, Edina, Minnesota 55439.

04-03-2026

Alliant Energy Corporation entered into a $400M Credit Agreement dated March 2, 2026, with U.S. Bank National Association as Administrative Agent and CoBank, ACB; Mizuho Bank, Ltd.; and TD Securities (USA) LLC as Joint Lead Arrangers and Joint Book Runners. The facility provides an Aggregate Commitment of $400M, with Applicable Margins of 0.00% for Base Rate Borrowings and 0.85% for Term SOFR Borrowings. No prior period comparisons are available as this is a new financing arrangement.

• ·Filing Date: March 04, 2026
• ·Agreement effective date: March 2, 2026
• ·Alternate Base Rate defined as highest of zero, Prime Rate, Federal Funds Effective Rate + 0.50%, or Term SOFR (1-month) + 1.00%

04-03-2026

Cricut, Inc. reported FY2025 total revenue of $709M, down 1% YoY from $713M due to a 5% decline in Products revenue to $381M, despite 5% growth in Platform revenue to $327M. Gross profit rose 11% to $390M with margin expansion to 55% (Platform at 89%, Products up to 26%), driving operating income up 26% to $96M and net income up 22% to $77M. However, sales and marketing expenses increased 11% to $159M while R&D rose 10% to $67M.

• ·Stock-based compensation expense declined to $35M in FY2025 from $45M in FY2024.
• ·Provision for income taxes increased 20% YoY to $31M in FY2025.
• ·Total revenue down 7% from FY2023 $765M peak.
• ·G&A expenses down 6% YoY to $68M but flat at 10% of revenue.

04-03-2026

News Corporation disclosed via 8-K information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program authorizing purchases of Class A (NWSA) and Class B (NWS) common stock. The disclosures are attached as Exhibits 99.1 and 99.2, which include forward-looking statements on potential repurchases subject to market conditions and other factors. No specific repurchase transactions or amounts were detailed in the filing body.

• ·Event date: March 3, 2026
• ·Filing date: March 4, 2026
• ·Securities: Class A Common Stock (NWSA, par value $0.01), Class B Common Stock (NWS, par value $0.01) on Nasdaq Global Select Market

04-03-2026

NexGen Energy Ltd. filed its Form 40-F annual report for FY ended December 31, 2025, incorporating the Annual Information Form, MD&A, and audited IFRS financial statements for 2025 and 2024, with 659,960,072 common shares outstanding. Short-term compensation to key management personnel decreased 1.4% YoY to $5,950, while share-based payments increased 30.9% YoY to $32,397. Management confirmed effective disclosure controls and no material changes in internal controls over financial reporting.

• ·Audited by KPMG LLP (Auditor Firm ID: 85)
• ·Principal executive offices: Suite 3150, 1021 West Hastings Street, Vancouver, B.C., Canada V6E 0C3
• ·Agent for service in US: Puglisi & Associates, 850 Library Avenue, Suite 204, Newark, Delaware 19711
• ·No off-balance sheet arrangements material to investors
• ·No changes in internal control over financial reporting during FY2025

04-03-2026

Gran Tierra Energy Inc. reported 2025 average WI production of 45,709 BOEPD, up 32% YoY, with Q4 at 46,344 BOEPD (+13% YoY, +9% QoQ), and South American reserves replacement exceeding 100% for PDP and 2P, achieving before-tax 2P NAV of $1.8B. However, Adjusted EBITDA fell 23% YoY to $284M due to lower Brent prices, operating netback declined 37% to $20.18/boe, sales dropped 4% to $597M, and the company posted a net loss of $193M versus 2024 profit. Subsequent bond exchange reduced debt with 88% participation, extending maturities to 2031, and pro forma net debt of $533M, while entering Azerbaijan EDPSA.

• ·Canadian reserves replacement negative due to reclassification to contingent resources from lower gas prices; Canada represents 39% of 1P and 44% of 2P reserves.
• ·Operating expenses up 23% to $248.7M YoY; per boe down 6% to $15.17.
• ·Cash G&A costs up 37% to $56.9M; per boe up to $3.47.
• ·Bond buybacks: $21.3M face value at 20% discount.
• ·Azerbaijan EDPSA: 65% WI to Gran Tierra, 250 sq km 3D seismic, 2 wells in 36 months.
• ·Safety: TRIF 0.02 in 2025, top quartile; restored/protected 5,600 hectares.
• ·Future development costs: $888M (1P), $1,682M (2P).

04-03-2026

General Fusion's Chief Strategy Officer Megan Wilson highlighted the company's focus on practical fusion power and the January 21, 2026 Business Combination Agreement with Spring Valley Acquisition Corp. III (SVAC) during a fireside chat at the FusionX:Global Summit on March 3, 2026, noting that the deal provides capital for LM26 milestones. The transaction involves SVAC's continuation to British Columbia, amalgamation with General Fusion via NewCo, and renaming to General Fusion Group Ltd. However, the filing emphasizes significant risks including potential failure to complete the deal, regulatory hurdles, employee retention issues, and commercialization challenges for magnetized target fusion.

• ·Business Combination Agreement dated January 21, 2026
• ·Joint Registration Statement on Form F-4 filed with SEC, including preliminary proxy statement/prospectus
• ·SVAC Final Prospectus dated September 3, 2025, filed September 4, 2025
• ·Filing Date: March 04, 2026; Communication Date: March 3, 2026

04-03-2026

Procaccianti Hotel REIT, Inc. announced on March 2, 2026, that share repurchases for the quarter ended December 31, 2025, under its Amended and Restated Share Repurchase Program are prorated due to the funding limitation being reached, with insufficient DRIP proceeds to fulfill all requests. Deceased stockholders' shares will be repurchased in full, but remaining requests will only be honored at approximately 3.6% pro rata, with no requests from qualifying disabilities or small accounts (≤100 shares). This reflects constraints under the program's 5.0% annual share limit and funding caps, potentially delaying liquidity for other shareholders.

• ·Repurchase priorities: (1) deceased stockholders (full, pro rata if insufficient funds), (2) qualifying disabilities or involuntary exigent circumstances (e.g., bankruptcy) and small accounts ≤100 shares, (3) remaining requests pro rata.
• ·Unfulfilled repurchase requests automatically carry over to subsequent periods unless withdrawn 5 business days prior to next repurchase date.
• ·Death-related repurchases count toward 5.0% share limit but are exempt from percentage cap.

04-03-2026

Pelican Acquisition Corporation filed a DEFA14A on March 4, 2026, announcing a Prospectus Supplement dated March 3, 2026, to the S-4 prospectus, clarifying that warrants of Pelican Holdco, Inc. (PubCo) will not be listed or traded on Nasdaq or any exchange. This update relates to the pending business combination with Greenland Exploration Limited and March GL Company, with no other changes to the prospectus. The filing serves as soliciting material ahead of the Pelican Shareholder Meeting to approve the transaction.

• ·S-4 Registration Statement (No. 333-291171) declared effective February 17, 2026; original prospectus dated February 18, 2026.
• ·Pelican 10-Qs filed for quarters ended October 31, 2025 (Dec 19, 2025), July 31, 2025 (Sep 15, 2025), April 30, 2025 (Jun 27, 2025); S-1 effective May 22, 2025.
• ·Ordinary shares par value $0.0001 per share.

04-03-2026

MOVING iMAGE TECHNOLOGIES INC. (MITQ) issued a DEFA14A additional proxy statement for its Annual Meeting of Stockholders on March 12, 2024, at 10:00 a.m. local time. Proposals include electing five directors for a one-year term expiring at the 2025 annual meeting and ratifying Haskell & White LLP as independent auditors for the fiscal year ending June 30, 2024. The Board recommends voting 'FOR' both proposals.

• ·Meeting location: 17760 Newhope Street, Suite B, Fountain Valley, CA 92708
• ·Fiscal year reference for audit ratification: ending June 30, 2024
• ·Prior year reference: year ended June 30, 2023 (investor site link)

04-03-2026

Enhabit, Inc. entered into an Amended and Restated Credit Agreement dated February 26, 2026, which amends and restates the existing Credit Agreement dated June 1, 2022. Wells Fargo Bank, National Association serves as Administrative Agent, Collateral Agent, and Swingline Lender, with multiple banks including BofA Securities, Inc., Capital One, N.A., Regions Bank, JPMorgan Chase Bank, N.A., and Citizens Bank, N.A. acting as Joint Lead Arrangers and Joint Bookrunners. The agreement outlines standard terms for commitments, loans, borrowings, and covenants, with no specific facility sizes or rates detailed in the provided excerpt.

• ·Existing Credit Agreement originally dated June 1, 2022.
• ·SEC 8-K Filing Date: March 04, 2026.
• ·Items reported: 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), 9.01 (Financial Statements and Exhibits).

04-03-2026

On March 3, 2026, the Board of Directors of Innovative Industrial Properties, Inc. approved a new share repurchase program authorizing the repurchase of up to $100 million of the Company's common stock, replacing the existing program scheduled to expire on March 17, 2026. Repurchases may occur through open market purchases, block trades, privately negotiated transactions, or via a Rule 10b5-1 plan, in compliance with Rule 10b-18 and subject to market conditions and management discretion. The program expires on March 4, 2027, and may be suspended, modified, or discontinued at any time.

• ·Securities registered: Common Stock (IIPR) and Series A Preferred Stock (IIPR-PA) on New York Stock Exchange
• ·Repurchases subject to Rule 10b-18 compliance and potential Rule 10b5-1 plan adoption

04-03-2026

Mitek Systems, Inc. held its annual stockholder meeting on March 3, 2026, with 38,435,860 shares represented out of 45,299,662 outstanding, where all five proposals were approved by stockholders. Eight directors were elected with strong support (For votes ranging from 27.2M to 30.1M), auditors BDO USA, P.C. were ratified (37.9M For), and the Amended ESPP was approved overwhelmingly (30.3M For). However, advisory approval of executive compensation received notable opposition (5.6M Against out of 30.5M voted) as did the Amended 2020 Incentive Plan (4.6M Against out of 30.5M voted).

• ·Director election withheld votes highest for Kimberly S. Stevenson (3,306,140)
• ·Proxy statement filed with SEC on January 26, 2026
• ·Fiscal year ends September 30, 2026

04-03-2026

Corvex, Inc. announced on March 3, 2026, the verified production deployment of confidential computing for AI on NVIDIA HGX B200 systems, featuring encrypted GPU-to-GPU communication and remote attestation for secure AI workloads with near-native performance. This achievement supports secure multi-tenant AI environments and is highlighted in the context of Corvex's definitive all-stock merger agreement with Movano Inc. (Nasdaq: MOVE), announced on November 10, 2025. No financial metrics or performance comparisons were disclosed.

• ·Definitive merger agreement (Merger Agreement) announced November 10, 2025
• ·Form S-4 registration statement File No. 333-292321 contains proxy statement/prospectus
• ·Merger is an all-stock transaction
• ·Movano Commission File No.: 001-40254
• ·Movano Annual Report on Form 10-K for year ended December 31, 2024

04-03-2026

This DEF 14A proxy statement solicits shareholder votes for the election of board members at the virtual annual meeting on April 16, 2026, for Nuveen Virginia Quality Municipal Income Fund (NPV) and 15 other Nuveen funds. For NPV, holders of Common and Preferred Shares vote together to elect four Class II Board Members, while Preferred Share holders vote separately to elect two Board Members. The record date is February 9, 2026, with no financial performance metrics disclosed.

• ·Annual Meeting: April 16, 2026, at 2:00 p.m. Central Time, virtual only via meetnow.global/M6VY4FD
• ·Record date: February 9, 2026
• ·Proxy materials mailed on or about March 6, 2026
• ·Quorum: Majority of shares for most votes; 33 1/3% of Preferred Shares for their separate election
• ·Registration for virtual attendance required 3 business days prior if held by intermediary

04-03-2026

Nuveen Variable Rate Preferred & Income Fund (NPFD), along with multiple other Nuveen funds, has issued a joint proxy statement for its virtual Annual Meeting of Shareholders on April 16, 2026, primarily to elect Board Members. For NPFD, this includes electing four Class II Board Members by holders of Common and Preferred Shares voting together as a single class, and two Board Members by Preferred Shares holders voting separately. The record date for shareholders entitled to vote is February 9, 2026, with no financial performance data or changes reported.

• ·Annual Meeting held virtually via live webcast at meetnow.global/M6VY4FD, 2:00 p.m. Central Time on April 16, 2026; no physical location.
• ·Quorum requires majority of shares entitled to vote, or 33 1/3% for Preferred Shares election of two Board Members.
• ·Proxy mailed on or about March 6, 2026; registration for intermediary-held shares required 3 business days prior.
• ·Shares located at 333 W. Wacker Drive, Chicago, IL 60606.

04-03-2026

This DEF 14A proxy statement for Nuveen Real Estate Income Fund (JRS) and 15 other Nuveen funds solicits shareholder votes for the virtual annual meeting on April 16, 2026, at 2:00 p.m. Central time to elect board members, including four Class II Board Members for JRS voted by common shareholders. No financial performance data or other metrics are disclosed; the filing is purely procedural for governance.

• ·Record date: February 9, 2026
• ·Proxy materials mailed on or about March 6, 2026
• ·Virtual meeting via meetnow.global/M6VY4FD; intermediaries must register 3 business days prior with legal proxy by 5:00 p.m. ET
• ·Quorum: majority of shares for most votes; 33 1/3% of Preferred Shares for certain elections
• ·SEC File Number: 811-10491; CIK: 0001158289

04-03-2026

This DEF 14A filing is a joint proxy statement for the annual shareholder meetings of multiple Nuveen closed-end funds, including Nuveen Real Asset Income & Growth Fund (JRI), scheduled virtually on April 16, 2026, at 2:00 p.m. Central time. Shareholders of record as of February 9, 2026, will vote to elect board members, with JRI seeking election of four Class II Board Members by common shareholders. No financial performance data or period comparisons are provided; the filing outlines voting procedures, quorum requirements, and virtual attendance details.

• ·Record date: February 9, 2026
• ·Proxy materials mailed on or about March 6, 2026
• ·Virtual meeting access: meetnow.global/M6VY4FD
• ·Registration for intermediary-held shares required 3 business days prior, by 5:00 p.m. ET
• ·Quorum: majority of shares entitled to vote; 33 1/3% for Preferred Shares elections in select funds

04-03-2026

Rise Gold Corp. entered a strategic 18-month development partnership with Morgan Hughes Energy to advance the Idaho-Maryland Mine as a gold and critical-minerals project, issuing 18 million warrants at $0.40 strike price and offering a potential $1.5M milestone payment upon securing capital commitments. Morgan Hughes will support planning, capital formation, and positioning within U.S. critical-minerals initiatives. However, the company faces ongoing regulatory hurdles, including a denied Use Permit by Nevada County Supervisors and a pending Writ of Mandamus with oral arguments on March 6, 2026.

• ·Warrants vest in tranches: 9M on critical-minerals framework advancement, 4.5M on development support, 4.5M on capital commitments.
• ·Morgan Hughes board seat upon qualifying milestone if maintaining 5% ownership.
• ·Alternative to reimbursement: 1.8M warrants for 12 months upon mutual agreement.
• ·I-M Mine historical grades: gold 0.50 oz/ton (17.1 g/t), no domestic U.S. tungsten mine since 2015.
• ·Writ of Mandamus filed May 2024 challenging denial of Use Permit and vested rights.

04-03-2026

Babcock & Wilcox reported Q4 2025 revenue of $161.0 million, essentially flat YoY compared to $161.8 million, but delivered strong profitability with operating income of $12.2 million (up from $2.6 million) and Adjusted EBITDA of $16.4 million (53% increase from $10.7 million). Full year 2025 revenue increased slightly by 1.2% to $587.7 million alongside a 107% surge in Adjusted EBITDA to $43.7 million, though the company still recorded a $32.8 million loss from continuing operations (improved from $104.3 million prior year). Key highlights include signing full notice to proceed on a $2.4 billion AI data center project with Base Electron, boosting continuing operations backlog to $2.8 billion (470% YoY increase) and reducing net debt to $119.7 million.

• ·Paid off outstanding bonds due February 2026 in December 2025; plans to pay off December 2026 bonds in 2026.
• ·Earnings conference call scheduled for March 16, 2026 at 5 p.m. ET.
• ·Extended maturity date of Axos facility.

04-03-2026

FactSet announced the appointments of Kate Stepp as Chief AI Officer and Bob Stolte as Chief Technology Officer, effective March 2, 2026, to accelerate enterprise AI and platform strategy, with both reporting to CEO Sanoke Viswanathan. Kate Stepp previously served as CTO since September 2022, focusing on client-centric technology and AI expansion. These leadership changes reinforce FactSet's commitment to AI innovation, serving more than 9,000 global clients and 239,000 users across 19 countries.

• ·Kate Stepp held the role of Chief Technology Officer since September 2022.
• ·Appointments announced on March 4, 2026.

04-03-2026

Somnigroup International Inc. (SGI) is hosting an Investor Day on March 4, 2026, with executive management presentations on the company's strategic vision, growth initiatives across business units, multi-year financial targets, and capital allocation strategy, followed by a Q&A session. The event is invitation-only in-person due to capacity limits but available via live webcast on the IR website at www.somnigroup.com starting at 8:00 a.m. ET, with replay and materials posted afterward. No financial results or performance metrics were disclosed in this announcement.

• ·Securities traded on New York Stock Exchange under ticker SGI (Common Stock, $0.01 par value)
• ·Principal executive offices: 100 Crescent Ct. Suite 700, Dallas, Texas 75201
• ·Information under Item 7.01 not deemed 'filed' under Section 18 of the Exchange Act

04-03-2026

Altisource Portfolio Solutions S.A. reported total revenue of $171M for the year ended December 31, 2025, up 7% YoY from $160M, driven by 16% growth in Origination service revenue to $35M and 5% increase in Servicer and Real Estate to $126M. However, gross profit declined 1% to $49M with margins contracting to 30% from 33%, income from operations fell 87% to $0.4M impacted by a $7.5M litigation settlement loss, and Marketplace revenue dropped 10% to $24M while Technology and SaaS Products declined 11% to $9M. The company achieved a net income attributable to Altisource of $1.6M, swinging from a $36M loss in 2024, supported by a 69% reduction in interest expense.

• ·REO Inventory - Customers other than Rithm increased 230% to 2.4 (in thousands) as of Feb 15, 2026 from 0.7.
• ·REO Inventory - Rithm remained flat at 1.0 (in thousands) as of Feb 15, 2026.
• ·Corporate and Others segment reported operating loss of $32.8M in 2025 vs $34.8M in 2024.
• ·SG&A expenses decreased 10% to $41M in 2025.
• ·Filing date: March 04, 2026 for year ended December 31, 2025.

04-03-2026

EyePoint Pharmaceuticals reported Q4 2025 net revenue of $0.6M, down 95% YoY from $11.6M, and full-year revenue of $31.4M, down 28% from $43.3M, primarily due to lower license and royalty revenue recognition from the YUTIQ agreement, while operating expenses rose 25% to $71.0M in Q4 and 45% to $274.8M for the year driven by Phase 3 trials. Net losses widened to $67.6M ($0.81/share) in Q4 and $232.0M ($3.17/share) for the year. However, cash and investments stood at $306M, providing runway into Q4 2027, with DURAVYU Phase 3 wet AMD trials (LUGANO/LUCIA) on track for mid-2026 topline data and first patients dosed in DME trials (COMO/CAPRI).

• ·U.S. patent issued in February 2026 extending DURAVYU insert formulation coverage into 2043.
• ·Manufacturing of registration batches for DURAVYU completed at Northbridge, MA facility for NDA CMC section.
• ·DSMC recommended continuation of Phase 3 wet AMD program with no modifications after second review.

04-03-2026

Trio Petroleum Corp amended its Prospectus Supplement under the January 9, 2026 ATM Agreement with Ladenburg Thalmann & Co. Inc., reflecting prior sales of 9,254,648 shares of Common Stock for $6.89M, increasing the maximum aggregate offering amount to $13.38M with $6.49M in shares now available for sale. Amendment No. 1 (March 3, 2026) updated availability to $3.29M after initial $3.60M sales of $3.60M (7.34M shares), while Amendment No. 2 (March 4, 2026) further adjusted figures. No performance metrics or financial impacts from proceeds are disclosed.

• ·Registration Statement on Form S-3 (File No 333-281813) effective September 10, 2024.
• ·January 9th 8-K filed reporting entry into ATM Agreement.
• ·ATM Agreement incorporated by reference as Exhibit 10.1 from January 9, 2026 8-K.

04-03-2026

H.B. Fuller Company filed definitive additional proxy materials (DEFA14A) on March 04, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee is required and is marked as definitive additional materials. No financial metrics, proposals, or other substantive details are provided in the excerpt.

04-03-2026

Dycom Industries reported record FY2026 contract revenues of $5.546B, up 17.9% YoY (6.5% organically), with Adjusted EBITDA rising 28.0% to $737.7M at 13.3% margin; Q4 revenues hit a record $1.458B, up 34.4% YoY (16.6% organically) and Adjusted EBITDA up 39.6% to $162.4M. However, Q4 GAAP net income declined 50.1% to $16.3M due to acquisition-related costs, despite annual net income growth of 20.5% to $281.2M. The company completed the acquisition of Power Solutions on Dec 23, 2025, adding entry into data centers, and provided FY2027 revenue outlook of $6.85B-$7.15B.

• ·Revised segment reporting to Communications and Building Systems effective Q4 FY2026.
• ·FY2027 outlook: Contract revenues $6.85B to $7.15B (Communications $5.70B-$5.90B, Building Systems $1.15B-$1.25B).
• ·Q1 FY2027 outlook: Revenues $1.64B-$1.71B, Adjusted EBITDA $202M-$218M, Adjusted Diluted EPS $2.57-$2.90.

04-03-2026

Applied Digital Corporation's subsidiary, APLD ComputeCo 2 LLC, priced an offering of $2.15 billion aggregate principal amount of 6.750% senior secured notes due 2031 at 98% of par, expected to close on or around March 10, 2026. Net proceeds will fund development and construction of 200 megawatts of critical IT load at the Polaris Forge 2 AI Factory campus in Harwood, North Dakota, which is leased to Oracle, along with project accounts and related fees. No prior period comparisons or performance metrics are provided in the filing.

• ·Notes to be sold to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S.
• ·Campus located in Harwood, North Dakota.

04-03-2026

SSR Mining Inc. entered a binding memorandum of understanding to sell its 80% ownership in the Çöpler mine and related properties to Cengiz Holding A.S. for $1.5B in cash, payable at closing, with a $100M deposit and $50M reciprocal break fee. The transaction excludes the Hod Maden development project, is expected to close in Q3 2026 subject to Turkish regulatory approvals and limited due diligence, and is deemed fair by CIBC's fairness opinion. Proceeds will fund reinvestment, capital returns, and growth, repositioning the portfolio toward Americas operations including the Cripple Creek & Victor mine.

• ·Fairness opinion issued by CIBC World Markets Inc. on March 3, 2026
• ·Transaction not subject to financing contingency or operational permits
• ·Legal advisors: Allen Overy Shearman Sterling LLP
• ·Expected closure: third quarter of 2026
• ·SSR Mining retains 20% interest in Hod Maden project

04-03-2026

The Real Brokerage Inc. (REAX) filed its Form 40-F Annual Report for the fiscal year ended December 31, 2025, incorporating by reference its Annual Information Form, audited consolidated financial statements, and Management’s Discussion and Analysis. The company reported 210.5 million outstanding common shares as of December 31, 2025, with no long-term debt, capital leases, operating leases, purchase obligations, or other long-term liabilities (all $0). No material changes in internal control over financial reporting were noted, and the Audit Committee is led by financial expert Larry Klane.

• ·No changes in internal control over financial reporting during FY 2025.
• ·No off-balance sheet arrangements.
• ·Shareholder quorum requirement: at least 5% of issued common shares.
• ·Exempt from certain Nasdaq rules as foreign private issuer (e.g., proxy solicitation follows Canadian rules).
• ·Code of Business Conduct and Ethics applies to all directors, officers, and employees.

04-03-2026

Nuveen Quality Municipal Income Fund extended the final mandatory redemption date for its Series 1 Variable Rate Demand Preferred Shares ($236.8M aggregate liquidation preference) and Series 2 Variable Rate Demand Preferred Shares ($267.5M aggregate liquidation preference) from September 11, 2026, to September 11, 2056, effective March 3, 2026. This extension applies to these senior securities, which rank ahead of common shares (NAD) in liquidation and dividends, with weekly dividend rates set by a remarketing agent and liquidity support from a provider. No performance declines or flat metrics were reported in this disclosure.

• ·Dividends on VRDPs set weekly by remarketing agent, subject to maximum rate that increases during extended unsuccessful remarketing.
• ·Liquidity feature allows holders to sell to liquidity provider if remarketing fails.
• ·VRDPs not registered under Securities Act of 1933; disclosure not an offer to sell.

04-03-2026

On March 3, 2026, the NYSE suspended trading in Vicarious Surgical Inc.'s Class A common stock (RBOT) after determining the company's average global market capitalization fell below the $15M threshold over a consecutive 30 trading day period under Section 802.01B, and commenced delisting proceedings via Form 25 following any appeal. The company is evaluating an appeal within 10 business days and has approval to quote on the OTCID market tier starting March 4, 2026, but this shift to a less liquid OTC market is expected to depress the stock price, reduce liquidity, limit equity financing access, and impair employee equity incentives. No positive financial metrics or performance improvements were reported.

• ·Appeal of delisting determination must be filed within 10 business days of March 3, 2026 notification.
• ·Company headquartered at 78 Fourth Avenue, Waltham, MA 02451.

04-03-2026

European Wax Center, Inc. reported FY 2025 total revenue of $206.6M, down 4.7% YoY from $216.9M, with system-wide sales at $947.3M (-0.4%) and same-store sales up a flat 0.2%; however, net centers decreased 1.9% to 1,047, GAAP net income fell 19.2% to $11.9M, and Adjusted EBITDA declined 3.0% to $73.3M. In Q4 FY2025, revenue dropped 9.3% to $45.1M, system-wide sales decreased 1.6% to $225.6M with same-store sales down 0.1%, leading to a net loss of $1.5M and Adjusted EBITDA down 33.1% to $12.7M. The company also noted its agreement to be taken private by General Atlantic and repurchased 1.4M shares for $5.7M.

• ·Franchisees opened 11 and closed 31 centers in FY 2025.
• ·Net cash provided by operating activities: $53.0M in FY 2025.
• ·SG&A as % of revenue increased 110 bps to 28.2% in FY 2025.
• ·Cumulative repurchases under $50M authorization: $45.9M.
• ·No outstanding borrowings under revolving credit facility at FY end.

04-03-2026

Bath & Body Works reported Q4 2025 net sales of $2.7B, down 2% YoY from $2.8B, with adjusted EPS of $2.05 slightly below prior year's $2.09, though results exceeded guidance; FY 2025 net sales were $7.3B, down 0.2% YoY, with adjusted EPS of $3.21 versus $3.29 last year and operating income declining to $1.1B from $1.3B. The company repurchased $400M in shares and ended with $953M in cash, up from $674M, but FY 2026 guidance projects net sales down 2.5-4.5% and adjusted EPS of $2.40-$2.65.

• ·U.S./Canada stores sales down 2.6% in Q4 but up 0.9% FY; Direct channel down 5.4% FY; International up 8.6% Q4 and 4.9% FY.
• ·Net cash from operating activities $1.1B in FY2025, up from $886M.
• ·Long-term debt reduced to $3.6B from $3.9B.
• ·Q1 2026 adjusted EPS guidance $0.24-$0.30 vs. $0.49 reported in Q1 2025.

04-03-2026

TScan Therapeutics reported Q4 and FY 2025 financial results with revenue surging 286% YoY to $2.6M in Q4 and 267% to $10.3M FY due to Amgen collaboration timing, alongside QoQ declines in R&D (-32% to $20.0M) and G&A (-20% to $6.4M) expenses from heme program prioritization. However, FY net loss widened slightly 2% YoY to $129.8M, cash decreased 15% to $152.4M (sufficient into H2 2027), and the solid tumor PLEXI-T trial was discontinued. Positive clinical progress included favorable ASH data for TSC-101 (100% relapse-free at 2 years in treated vs 25% control), FDA IND clearances for TSC-102-A01/A03, and Cohort C enrollment completion in ALLOHA trial.

• ·FDA cleared INDs for TSC-102-A01 and TSC-102-A03 in Feb 2026 targeting CD45 in HLA-A*01:01 and A*03:01 patients.
• ·Upcoming: Q2 2026 Cohort C data and TSC-101 pivotal trial launch; H2 2026 updated Cohort C data and TSC-102 Phase 1 start.
• ·ASH data: TSC-101 overall survival HR=0.61 (p=0.52).
• ·Total assets $228.8M as of Dec 31, 2025 (down from $371.1M prior year).

04-03-2026

Holley reported strong Q4 2025 results with net sales up 10.9% YoY to $155.4M, net income of $6.3M versus a $37.8M loss last year, and Adjusted EBITDA up to $33.2M from $29.1M. For full year 2025, net sales grew modestly 1.9% to $613.5M with Adjusted EBITDA rising to $124.0M from $110.5M; however, free cash flow declined to $34.2M from $41.8M, adjusted net income fell to $21.2M from $24.8M, and overall sales growth was supported mainly by core business excluding divestitures.

• ·Core business net sales excluded $3.2M non-core in Q4 2024 and $26.8M for FY 2024.
• ·Net debt to EBITDA leverage ratio of 3.75x at FY 2025 end, below 4.0x target.
• ·Total debt prepayments of $100M since September 2023.
• ·Generated ~$20M cost savings for FY 2025.
• ·FY 2026 guidance: Net Sales $625-655M; Adjusted EBITDA $127-137M.
• ·Conference call on March 4, 2026 at 8:30 a.m. ET.

04-03-2026

Post Holdings, Inc. announced on March 4, 2026, its intention to commence a private offering of $500M aggregate principal amount of 6.250% senior notes due 2034 to eligible purchasers, subject to market conditions. The net proceeds will repay the outstanding balance of its revolving credit facility as of December 31, 2025, with any remainder for general corporate purposes such as debt repayment, share repurchases, acquisitions, capital expenditures, or working capital. No financial performance metrics or period comparisons were disclosed.

• ·Offering subject to market and other conditions
• ·Press release attached as Exhibit 99.1

04-03-2026

Cellectar Biosciences reported 2025 financial results with cash and equivalents declining 43% to $13.2M from $23.3M, sufficient to fund operations into Q3 2026, alongside sharp reductions in R&D expenses (down 56% to $11.5M) and G&A (down 55% to $11.5M), resulting in a narrower net loss of $21.8M ($8.35/share) versus $44.6M ($36.52/share) in 2024. Pipeline advancements include plans for Q3 2026 Conditional Marketing Authorization submission to EMA for iopofosine I 131 in Waldenström Macroglobulinemia, FDA Breakthrough Therapy Designation, and initiation of a Phase 1b study for CLR 125 in triple negative breast cancer with data expected mid-2026. However, ongoing cash burn and lack of revenue underscore funding risks ahead of key milestones.

• ·Common shares outstanding increased to 4,240,129 from 1,535,996 YoY.
• ·Phase 1b CLR 125 study evaluates doses of 32.75 mCi/m²/dose (up to 4 cycles), 62.5 mCi/m²/dose (up to 3 cycles), and 95 mCi/m²/dose (up to 2 cycles).
• ·Secured supply agreement with Ionetix for cGMP-grade Actinium-225 (Ac-225) and Astatine-211 (At-211).

04-03-2026

Daktronics reported fiscal Q3 2026 sales of $181.9 million, up 21.6% YoY from $149.5 million, with new orders at $201.1 million (+7.6% YoY) and product backlog rising 25.3% YoY to $342.3 million; operating income turned positive at $1.9 million from a $3.6 million loss, and net income was $3.0 million versus a $17.2 million loss. However, gross profit margin dipped slightly to 24.0% from 24.6% YoY due to revenue mix shifts, operating expenses rose modestly to $41.7 million from $40.4 million, and order growth was partially offset by declines in Live Events and International units.

• ·Acquired Display Business from XDC on Dec 22, 2025, consisting of IP, equipment, and other assets; did not materially impact financials.
• ·Entered $71.5M senior credit facility on Nov 26, 2025, enhancing financial flexibility.
• ·Working capital ratio of 2.2 to 1 at Q3 FY2026 end.
• ·Effective tax rate 14.3% in Q3 FY2026 vs 3.7% in Q3 FY2025.

04-03-2026

Advanced Flower Capital Inc. (AFCG) reported Q4 2025 GAAP net income of $0.9 million ($0.04 per share) and full-year 2025 GAAP net loss of $20.7 million ($0.95 per share loss), while Distributable Earnings were negative at $(2.8) million ($(0.12) per share) for Q4 but positive at $8.7 million ($0.39 per share) for the full year. Net interest income reached $5.2 million in Q4 and $24.6 million for the year, supported by $6.6 million and $31.3 million in interest income, respectively, though high expenses of $7.8 million in Q4 and a $22.6 million provision for credit losses annually contributed to the GAAP loss. The board declared a $0.05 per share dividend for Q1 2026, payable April 15, 2026.

• ·Q4 2025 unrealized gains on loans at fair value: $3.5M
• ·FY 2025 unrealized losses on loans at fair value: $7.9M
• ·Q4 2025 management and incentive fees, net: $0.7M (after $0.2M rebate)
• ·FY 2025 stock-based compensation: $6.8M
• ·FY 2025 BDC conversion expenses: $1.2M
• ·Basic weighted average shares Q4 2025: 22.7M; FY 2025: 22.2M

04-03-2026

Abercrombie & Fitch Co. reported record Q4 FY2025 net sales of $1.7B, up 5% YoY with comparable sales +1%, and FY2025 net sales of $5.3B, up 6% YoY with comparable sales +3%, driven by Hollister's 15% FY growth while Abercrombie declined 1% FY. However, FY operating margin fell to 13.3% from 15.0% prior year, Q4 margin dropped to 14.1% from 16.2%, and FY EPS was $10.46 vs $10.69 prior. The company repurchased 5.4M shares for $450M (11% of shares outstanding) and outlooked FY2026 net sales growth of 3-5% with operating margin of 12.0-12.5%.

• ·Cash and equivalents flat at ~$760M YoY; inventories up to $601M from $575M.
• ·Liquidity stable at $1.2B.
• ·FY2026 outlook includes Q1 sales growth 1-3%, op margin ~7%; assumes 15% US tariff impact (290bps Q1, 70bps FY).
• ·Depreciation and amortization $155M FY2025 vs $154M FY2024.

04-03-2026

On March 4, 2026, SharonAI Holdings Inc. (SHAZ) issued a press release announcing a strategic relationship with World Wide Technology for the deployment of large-scale high-performance compute infrastructure in Australia and Asia-Pacific. This partnership is intended to support the company's expansion in the region. No financial terms or quantitative details were disclosed in the filing.

• ·Company address: 745 Fifth Avenue, Suite 500, New York, NY 10151
• ·Securities: Class A Ordinary Common Stock, $0.0001 par value, trading as SHAZ on Nasdaq Stock Market LLC
• ·Emerging growth company status: Yes

04-03-2026

Astrana Health, Inc. updated its corporate presentation on March 4, 2026, for use at conferences and meetings, furnished as Exhibit 99.1 under Item 7.01. The filing discloses forward-looking statements regarding the expected filing of its Form 10-K for the year ended December 31, 2025, on or before the extension deadline following a Form 12b-25, with an anticipated material weakness in internal control over financial reporting and consistency of financial statements with prior earnings release. No financial metrics or period comparisons are provided in the filing.

• ·Form 10-K for year ended December 31, 2025, expected to be filed on or before Form 12b-25 extension deadline
• ·Expected material weakness in internal control over financial reporting

04-03-2026

Republic Airways Holdings Inc. reported Q4 2025 revenues of $464.1M, up 20.6% YoY from $384.8M, with net income of $5.0M ($0.12/share) and full-year revenues of $1.68B, up 13.7% YoY from $1.47B, achieving net income of $76.2M ($1.87/share). The company completed a debt-free merger with Mesa Air Group on November 25, 2025, adding 60 E175 aircraft and growing the fleet to 311 aircraft, while generating $322.0M in operating cash flow and holding $296.5M in cash despite total debt and lease liabilities of $1.2B. However, results were impacted by $26.3M in merger-related costs, $15.3M Q4 executive separation expenses, and $8.1M additional tax expense from non-deductible items, though adjusted metrics showed stronger performance with FY adjusted net income of $114.0M.

• ·29 additional E175 aircraft on order with deliveries through 2029.
• ·Secured $299.4M financing and made $231.6M debt repayments in FY 2025.
• ·2026 guidance: at least 865,000 block hours, capex ~$90M, debt extinguishment ~$165M.
• ·Q4 aircraft rent expense down to $0.7M from $0.9M YoY.

04-03-2026

On February 27, 2026, Timothy Go resigned from the Board of Directors of Celanese Corporation, effective as of that date. The resignation is not the result of any disagreement with the Company's operations, policies, or practices. The Board and Company expressed gratitude for Mr. Go’s service as a Director.

• ·Filing date: March 4, 2026
• ·Event reported date: February 27, 2026
• ·Registrant state of incorporation: Delaware
• ·Commission File Number: 001-32410
• ·IRS Employer Identification No.: 98-0420726

04-03-2026

Innventure, Inc. filed an 8-K on March 4, 2026, under Item 7.01 to disclose a press release announcing operating and financial milestones that demonstrate accelerating momentum across its operating companies and an improved capital outlook. The company, an emerging growth company listed on Nasdaq (INV), provided no specific quantitative details in the filing. No declines or flat performance were mentioned.

• ·Registrant is an emerging growth company.
• ·Common Stock (par value $0.0001) trades as INV on Nasdaq Stock Market, LLC.
• ·Principal executive offices: 6900 Tavistock Lakes Blvd, Suite 400, Orlando, Florida 32827.

04-03-2026

SmartRent reported Q4 2025 total revenue of $36.5 million, up 3% YoY from $35.4 million, driven by 13% ARR growth to $61.6 million, 20% higher hardware revenue, and positive Adjusted EBITDA of $0.2 million versus a $7.4 million loss prior year. However, full-year 2025 revenue fell 13% to $152.3 million from $174.9 million due to 30% lower hardware sales and flat hosted services, with net loss widening to $60.6 million including a $24.9 million goodwill impairment, and Adjusted EBITDA loss of $16.4 million worse than $9.9 million prior year. Units Deployed grew 10% to 890,870, supported by strong Q4 bookings up 24%, while maintaining $105 million cash and no debt.

• ·Hardware Units Shipped Q4 2025: 20,003 (-17% YoY)
• ·SaaS ARPU Q4 2025: $5.83 (+3% YoY)
• ·Q4 gross margin: 38.6% (+990 bps YoY)
• ·FY operating expenses reduced by $13.2M
• ·Remaining share repurchase authorization: $16.8M
• ·Hub amortization revenue expected < $5.0M in 2026

04-03-2026

SM Energy Company announced plans, subject to market conditions, to privately offer $750M aggregate principal amount of senior notes due 2034 and commence a cash tender offer for up to $750M of its outstanding $1.35B 8.375% senior notes due 2028, originally issued by Civitas Resources. The filing includes audited historical financial statements for Civitas for fiscal years ended December 31, 2025 and 2024, unaudited pro forma condensed combined financial information for SM Energy and Civitas, and Civitas' reserve report as of December 31, 2025. These transactions carry forward-looking risks including market conditions and closing contingencies.

• ·Notes offering exempt under Rule 144A and Regulation S; unregistered under Securities Act.
• ·Tender offer terms detailed in offer to purchase dated March 4, 2026.
• ·Civitas financial statements cover fiscal years ended December 31, 2025 and 2024.

04-03-2026

Orion Group Holdings reported full-year 2025 revenue of $852.3 million, up 7% YoY from $796.4 million, with Adjusted EBITDA rising 8% to $45.2 million and GAAP net income of $2.5 million versus a prior-year loss; gross profit increased 16% to $105.6 million driven by strong execution. However, total backlog declined 12% to $640 million from $729 million, with Marine backlog dropping 18% to $480 million despite Concrete backlog growth of 10% to $160 million, amid delayed customer decisions. The company completed a $60 million acquisition of J.E. McAmis, refinanced with a $120 million credit facility, and initiated 2026 guidance for revenue of $900-950 million (9% growth at midpoint) and Adjusted EBITDA of $54-58 million.

• ·Completed $120M UMB Credit Facility on Dec 23, 2025, with $60M revolver, $20M equipment term, $40M acquisition term, plus $25M accordion; interest SOFR +2.5-3.0%.
• ·As of Dec 31, 2025: unrestricted cash $1.6M, total debt $8M; borrowed $47M under new facility for J.E. McAmis acquisition.
• ·2026 guidance: Capex $25-35M; Adjusted EPS $0.36-0.42.
• ·J.E. McAmis has $1.4B pipeline and $34M in marine/real estate assets.
• ·Recent awards: $86M USACE shoreline project.

04-03-2026

LM Funding America reported its highest monthly Bitcoin production in February 2026 at 8.7 BTC mined (up 11.5% MoM from 7.8 BTC in January), with energized hashrate increasing slightly to 0.78 EH/s and total machines rising to 7,513 after deploying 300 Bitmain S21 XP miners. However, the company sold 18.1 BTC, resulting in Bitcoin HODL declining 2.6% MoM to 354.7 BTC valued at $23.8M ($1.11 per diluted share), while its stock closed at $0.40 on March 2; it also extended its $11M Galaxy Digital loan maturity to April 24, 2026.

• ·BTC sold in Feb 2026: 18.1 BTC
• ·Oklahoma hashrate: 0.55 EH/s (up from 0.54 EH/s MoM)
• ·Mississippi hashrate flat at 0.23 EH/s MoM
• ·Loan maturity extended from original to April 24, 2026

04-03-2026

Aeries Technology, Inc. held its 2026 Annual General Meeting on March 3, 2026, with a quorum of 68.4% of ordinary shares (34,321,846 Class A ordinary shares and 1 Class V ordinary share present out of 50,209,716 Class A outstanding). All five resolutions were approved, including the election of directors Alok Kochhar, Biswajit Dasgupta, Nina B. Shapiro, and Bhisham (Ajay) Khare; ratification of Manohar Chowdhry & Associates as auditors for FY ended March 31, 2026; and authorization for a share consolidation up to 1-for-10 ratio with related amendments to the memorandum and articles. Voting showed strong support with minimal opposition across all proposals.

• ·Authorized share capital: $50,500.0001 divided into 500,000,000 Class A ordinary shares of $0.0001 par value each, 1 Class V ordinary share, and 5,000,000 preference shares.
• ·Proxy statement filed with SEC on February 6, 2026; record date January 28, 2026 at 5:00 p.m. ET.
• ·Highest against votes: Resolution No. 3 (607,167 Class A against), No. 5 (626,006 Class A against), but all passed.

04-03-2026

Brown-Forman reported Q3 FY26 net sales up 2% to $1.1B (+1% organic) and operating income up 21% to $340M (flat organic), but year-to-date FY26 net sales declined 2% to $3.0B (flat organic) with operating income flat at $905M (-3% organic) and diluted EPS down 8% to $1.41. While Whiskey net sales grew 2% and Emerging markets/Travel Retail rose 16%/9%, declines hit Tequila (-6%), US (-8%), Developed International (-2%), Rest of Portfolio (-34%), and non-branded/bulk (-64%). The company completed a $400M share repurchase, boosted cash from operations to $709M (+$263M YoY), and reaffirmed FY26 outlook for low-single-digit organic declines in net sales and operating income.

• ·Gross margin expanded 50 bps to 59.9%; operating margin up 70 bps to 30.0%.
• ·FY26 outlook: organic net sales and operating income decline low-single digits; capex $110-120M; effective tax rate 19-21%.
• ·Regular quarterly dividend of $0.2310/share payable April 1, 2026 (record date March 9, 2026).
• ·Conference call held March 4, 2026 at 10:00 a.m. ET.

04-03-2026

Edible Garden AG Incorporated entered into a Note Purchase Agreement dated March 3, 2026, with Streeterville Capital, LLC, issuing a secured promissory note with $1.625M principal for a $1.5M purchase price, incorporating a $120K original issue discount and $5K transaction expenses. The note is secured by all company assets (excluding Tetra Pak-related property) and guaranteed by subsidiaries 2900 Madison Ave Holdings, LLC and Edible Garden Corp., providing immediate cash influx but imposing restrictive covenants limiting future debt, equity issuances, and liens. While offering liquidity, the high OID signals elevated financing costs amid ongoing obligations.

• ·Closing Date: March 3, 2026, via electronic signatures at offices in Lehi, Utah
• ·Collateral excludes all assets, equipment, or property purchased from Tetra Pak, Inc. (including replacements and proceeds)
• ·Covenants restrict Restricted Issuances, new liens (except Tetra Pak assets), subsidiary equity/debt changes, and require timely SEC filings and listing maintenance on NYSE/Nasdaq American

04-03-2026

A. O. Smith Corporation's DEF 14A Proxy Statement, filed March 4, 2026, solicits votes for the 2026 Annual Meeting on April 13, 2026, at The Ritz-Carlton in Charlotte, NC, including electing the Board of Directors (six by Class A Common stockholders, four by Common stockholders), an advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditors for FY 2026. Record date is February 17, 2026, with 25.9M Class A Common shares and 112.4M Common shares outstanding entitled to vote. The statement highlights the transition to new CEO Steve Shafer under Executive Chairman Kevin J. Wheeler, with no financial performance metrics or period-over-period comparisons provided.

• ·Class A Common Stock: 1 vote per share for all matters; Common Stock: 1 vote for directors, 1/10th vote for other matters.
• ·Quorum requires majority of outstanding shares; directors elected by plurality vote per class.
• ·Pre-registration for meeting required by April 10, 2026; stockholder list available April 3, 2026.

04-03-2026

Gulfport Energy Corporation entered into a purchase agreement on March 3, 2026, to repurchase 84,416 shares of its common stock from accounts managed by Silver Point Capital, L.P. at $204.22 per share, for a total of approximately $17.2 million, reflecting a 2.3% discount to the NYSE closing price on March 2, 2026. This repurchase is part of the company's existing $1.5B common share repurchase program and is expected to close on March 9, 2026, reducing remaining availability under the program.

• ·Filing dated March 4, 2026
• ·Date of earliest event: March 3, 2026

04-03-2026

Elutia Inc. announced on March 4, 2026, that it has regained compliance with Nasdaq's Minimum Bid Price Requirement, with its Class A common stock closing at $1.00 per share or higher for 10 consecutive business days from February 13 to February 27, 2026. The company also regained compliance with the Minimum Market Value of Listed Securities (MVLS) Requirement, achieving $35M or greater for 11 consecutive business days from January 21 to February 4, 2026. Both compliance matters, previously flagged in November and December 2025, are now closed.

• ·Initial non-compliance notifications: Minimum Bid Price on November 7, 2025; MVLS on December 23, 2025.
• ·Nasdaq determination letters: MVLS compliance on February 5, 2026; Minimum Bid Price on March 2, 2026.
• ·Press release attached as Exhibit 99.1.

04-03-2026

BIO-key International, Inc. (BKYI) secured a $1.04M one-year license renewal and expansion (up 30% YoY) for its biometric identity solution from a foreign retail bank customer since 2015, now serving 30M clients (up from 7M initially) and managing over 300M fingerprints. Year-end cash position stands at $2.7M, with anticipated renewals and collections providing sufficient liquidity to fund growth internally. No declines or flat metrics reported.

• ·Solution supports in-branch teller stations, assisted kiosks, ATMs, and KYC processes tied to national identity verification.
• ·Approximately 10,000 bank employees authenticate daily using fingerprint technology.

04-03-2026

On March 3, 2026, Hexcel Corporation entered into a Cooperation Agreement with Vision One Fund, LP and affiliates, appointing Neal J. Keating to the Board of Directors and Audit Committee, nominating him for the 2026 Annual Meeting, and limiting Board size to 10 directors until the 2026 Annual Meeting and 9 thereafter until the Expiration Date. Vision One Parties agreed to withdraw their 2026 Annual Meeting nominees, adhere to standstill restrictions, and vote for Board nominees. No financial terms or impacts were disclosed.

• ·Board size limited to no more than 10 directors until 2026 Annual Meeting and 9 directors from 2026 Annual Meeting until Expiration Date (earlier of 30 days prior to 2027 stockholder nomination deadline or 150 days prior to 2026 Annual Meeting one-year anniversary).
• ·Neal J. Keating, age 70, previously Chairman, President, and CEO of Kaman Corporation (2008-2020), Executive Chairman until 2021; COO of Hughes Supply; CEO of GKN Aerospace.
• ·Mr. Keating serves on Hubbell Incorporated board since 2010 (chairs nominating/governance committee); former lead director of Triumph Group (2022-July 2025) and Barnes Group Inc. (2023-2025).
• ·No arrangements or understandings other than Cooperation Agreement for appointment; no reportable related party transactions under Item 404(a).

04-03-2026

Grayscale Bittensor Trust (TAO) announced a change in the index used for valuing its Bittensor (TAO) holdings, switching from the Coin Metrics Real-Time Rate to the CoinDesk Bittensor Benchmark Rate effective March 6, 2026, for NAV and NAV per Share calculations. The new index employs a volume-weighted algorithm from Constituent Trading Platforms selected based on IOSCO-aligned criteria including market quality, security, regulatory compliance, and others. Detailed methodology covers platform selection, price determination every 5 seconds, outlier detection, inactivity adjustments, and contingency plans if the index is unavailable.

• ·Index Price calculated every 5 seconds over 24-hour period at 4:00 p.m. New York time on business days
• ·Registration Statement on Form 10 filed December 9, 2025
• ·Index License Agreement dated February 1, 2022
• ·Constituent Trading Platforms must serve customers in jurisdictions including US (FinCEN), UK (FCA), EU (MiCA), Hong Kong (SFC), Singapore (MAS), UAE (VARA, ADGM), Gibraltar (GFSC)

04-03-2026

04-03-2026

Camber Energy, Inc., through its indirect majority-owned subsidiary Viking Protection Systems, LLC, successfully completed live transmission-line validation testing of its patented Broken Conductor Protection Technology (BCPT) on a 138 kV transmission line approximately 63 miles in length, operated by a U.S. electric utility, on February 27, 2026. The BCPT, implemented in SEL-411L relays, detected simulated single-phase open-conductor conditions at both ends of the line in less than one second under live system loading, with no false operations during additional security tests. A Validation Report summarizing the results was issued on or about March 2, 2026, by co-inventor Robert Stuart, P.Eng.

• ·Validation test involved simulation of open-conductor conditions at both ends of the line.
• ·Trip logic and protection elements operated as designed, confirmed by relay sequence-of-events records and oscillography.
• ·Redacted Validation Report attached as Exhibit 99.2.

04-03-2026

Bunker Hill Mining Corp. filed an 8-K on March 4, 2026, announcing via press release (Exhibit 99.1) an update to its previously announced LIFE offering of C$30 million units on a best efforts basis and a reverse stock split. No specific outcomes, proceeds, or ratios for the offering or split were detailed in the filing.

04-03-2026

Microbot Medical Inc. issued a press release on March 4, 2026, commending the American Medical Association’s efforts to protect health care professionals from ionizing radiation. The press release is furnished as Exhibit 99.1 under Item 7.01 and is not deemed filed for liability purposes.

04-03-2026

Tivic Health Systems, Inc. (Nasdaq: TIVC) appointed Michael K. Handley as CEO effective March 4, 2026, succeeding Jennifer Ernst, who has led since the company's founding in 2016 and will continue supporting the transition. The leadership change supports a strategic pivot to late-stage immunotherapies and biopharma expansion via the Velocity Bioworks CDMO subsidiary. Handley brings over two decades of experience, including US approvals and commercialization of 17 products generating billions in revenue at Amgen and Genentech.

• ·Tivic founded in 2016; Annual Report on Form 10-K for year ended December 31, 2024, filed March 21, 2025.
• ·Velocity Bioworks is a wholly owned full-service CDMO subsidiary based in San Antonio, Texas.
• ·Entolimod™ is a TLR5 agonist in late-stage development for Acute Radiation Syndrome (ARS) under FDA’s Animal Rule.

04-03-2026

XFLH Capital Corporation announced on March 4, 2026, that holders of its IPO units (XFLHU) may elect to separately trade the ordinary shares and rights, with separate trading commencing on the NYSE on March 9, 2026, under symbols XFLH and XFLHR, respectively. Unseparated units will continue trading as XFLHU, and brokers must contact transfer agent Continental Stock Transfer & Trust Company to effect separations. The company issued a press release attached as Exhibit 99.1.

• ·Ordinary shares have $0.0001 par value
• ·Rights entitle holders to one-seventh (1/7th) of one ordinary share
• ·Registrant is an emerging growth company